How many investments has OrbiMed made?

OrbiMed has 338 tracked investments, 63 of which have exited, including 38 dated in the last 24 months.

What stage does OrbiMed invest at?

OrbiMed invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is OrbiMed's typical check size?

OrbiMed typically writes checks of $1M – $75M.

Where is OrbiMed located?

OrbiMed is headquartered in New York, US.

Does OrbiMed lead rounds?

Yes, OrbiMed leads investment rounds.

Who does OrbiMed co-invest with?

OrbiMed most often shares deals with Foresite Capital, RA Capital, Frazier Life Sciences, among 274 tracked co-investors.

OrbiMed

Crossover fundoperating company · company profile

New York · Seed–Late Stage · 92 people tracked

Also known as ORBIMED ADVISORS LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into OrbiMed

Paths you didn't know you had: your email and LinkedIn already hold routes to the OrbiMed team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

OrbiMed invests globally across the entire healthcare industry, from early-stage private companies to large multinational corporations. Its focus spans biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services, targeting innovations that improve patient outcomes and address unmet medical needs. With over 25 years of investing experience, the firm deploys capital across both public and private markets worldwide, backed by a team of scientific, medical, and investment professionals. The firm aims to support companies driving healthcare innovation and helping humanity live healthier, longer, and more productive lives.

Invests inAI & Machine Learning Biotech Digital Health Healthtech Longevity Medical Devices Asia-Pacific Europe Global Middle East & North Africa New York North America

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

Stage

Seed–Late Stage

Check

$1M – $75M

New York, NY, US

Leads rounds

Leads

Instruments

Equity · Debt

Founded

1989

Last 12 months

13 investments

AUM

$20.6B

Tracked investments

338

Unicorns

IPOs

Acquisitions

Team · 92 people

from the firm's website & curated & public directories

Ankesh Bhansali· Managing Director· Mumbai Metropolitan Regionin

Arun Sadhanandham· Managing Director· Mumbai, Maharashtra, Indiain

Arun Sadhanandham is a Managing Director in private equity at OrbiMed, where he works as an investment professional focused on the Asia market. He holds a degree from IIM Bangalore.

Carl L. Gordon· Managing Partner· New York City Metropolitan Areain

Carl Gordon, an MIT Ph.D. and CFA with early hands‑on ImClone experience, is a founding GP and Co‑Head of global private equity repeatedly named to Forbes' Midas List and media‑shy.

David Bonita· General Partner· New York, New Yorkin

David Bonita is a physician-investor (MD, Harvard; clinical work at Mass General) with over two decades investing, rising to General Partner in 2020, and board roles in oncology and therapeutics.

David Wang· Partner· Greater Chinain

David Wang is a Partner and Senior Managing Director on OrbiMed's Asia team, focused on Greater China, which he joined in 2011. He previously led healthcare investments in China as a Managing Director at WI Harper Group and served as Head of Business Development at Siemens Medical Solutions, overseeing molecular diagnostics and diagnostic imaging strategy. He co-founded personalized medicine company First Genetic Trust as EVP, chaired The SNP Consortium Management Committee while at Bristol-Myers Squibb, and holds an M.D. from Peking University Medical School and a doctorate in Developmental Biology from Caltech.

Dimitrios Weedon· Managing Director· United Kingdomin

Dina Chaya· Partner, Private Equity· Londonin

Dina Chaya is a Partner on OrbiMed's Private Equity team, which she joined in 2023, and has worked in healthcare private equity and venture capital since 2001. Before OrbiMed, she held roles at Omega Funds, NeoMed, 3i, and Index Ventures. She holds a B.A. in Natural Sciences from the University of Cambridge and a Ph.D. in Molecular and Cellular Biology from Paris VI University, and is a CFA charterholder.

Diyong Xu· Partner· New York, New Yorkin

Diyong Xu is a Partner at OrbiMed with a career progression spanning analyst, associate, vice president, and principal roles at the firm. His investment experience covers biotechnology, biopharmaceuticals, medical devices, and diagnostics across venture capital, private equity, and investment banking contexts.

Evan Caplan· Partner· San Francisco Bay Areain

Evan Caplan is a Partner at OrbiMed, which he joined in 2018, where he focuses on venture investments in therapeutics, medical devices, and healthcare technology and services. Before OrbiMed, he worked as an investment banker at J.P. Morgan, advising public and private biotech, medtech, and healthtech companies. He holds a B.A. from Middlebury College and both an M.D. and an M.B.A. from Harvard.

Geoffrey Hsu· Managing Partner· New York, New Yorkin

Geoffrey C. Hsu combines Harvard Medical School training and healthcare investment-banking experience with long-tenured public-equity portfolio management since 2005 and a London-listed biotech trust role, giving him cross-border market insight.

Matthew Rizzo· General Partner· New York, New York

Matthew Rizzo heads a royalty and credit team, directed over $6 billion in structured credit and royalty deals, and brings 30 years of healthcare experience including pharma licensing and acquisitions.

Mona Ashiya· General Partner· New York, New Yorkin

Mona Ashiya is a General Partner at OrbiMed, which she joined in 2010. She previously worked on J.P. Morgan's biotechnology equity research team and held positions at the Global Alliance for TB Drug Development and Harvard Business School. She holds a B.A. from the University of California, Berkeley, a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh, and completed a post-doctoral fellowship at the Dana Farber Cancer Institute.

Peter Thompson· General Partner· Bellevue, Washingtonin

Peter Thompson is a General Partner at OrbiMed, which he joined in 2010, with over 25 years of industry experience. He previously held executive roles at Becton-Dickinson and Chiron, co-founded and served as CEO of Trubion Pharmaceuticals, co-founded several OrbiMed portfolio companies, and worked at the National Cancer Institute after internal medicine training at Yale. He holds a bachelor's degree in Molecular Biology and Mathematics and a medical degree from Brown University, and is a board-certified internist and oncologist.

Stella Xing· Managing Director· Menlo Park, California, United Statesin

Steven D. Wang· Partner· Huangpu District, Shanghai, Chinain

Sunny Sharma· Partner· Mumbai, Maharashtra, Indiain

Partner at OrbiMed holding an M.D.

Sven H. Borho· Managing Partner· New York, New York

Sven H. Borho, a founding partner, leads public equities and portfolio management for listed healthcare strategies, uniquely combining specialist biomedical expertise with a science-first approach prioritizing biology and clinical science.

Tal Zaks· Partner· Newton, Massachusetts, United Statesin

Partner at OrbiMed holding both M.D. and Ph.D. degrees.

Trevor Polischuk· Partner· New York, New Yorkin

Trevor Polischuk joined OrbiMed in 2003 as the Global Pharmaceutical Analyst covering Japan, and became a Partner in 2011, later serving as co-Portfolio Manager of the Worldwide Healthcare Trust. He previously worked as a Senior Research Analyst covering the U.S. pharmaceutical industry at Lehman Brothers and began his career on the Pharmaceutical Global Marketing Planning team at Warner-Lambert. He holds a B.S. in Biology and a Ph.D. in Neuropharmacology and Gross Human Anatomy from Queen's University, as well as an M.B.A. from Queen's M.B.A. for Science & Technology program.

W. Carter Neild· Managing Partner· New York, New Yorkin

Carter Neild spearheads expansion into healthcare royalties and Asia-focused private investments, combining a hybrid background in alternatives and bank-affiliated asset management (UBS, First Chicago) with deep University of Chicago ties.

Yifu Liu· Managing Director· Huangpu District, Shanghai, Chinain

Brian Glowatz· Director of Tax· New York, New York, United States

Cason Kim· Director of Quantitative Research

Clay DeMarcus· Principal· Menlo Park, California, United Statesin

Clay DeMarcus is a Principal in Private Equity / Venture Capital at OrbiMed. He previously worked at Bank of America as a Vice President in Equity Research covering medical technology and as an Investment Banking Associate in the healthcare group, and earlier held a role in operations at Accenture Strategy. He holds an undergraduate degree from Vanderbilt University and an MBA from Emory University's Goizueta Business School.

Corey Schrader· Director of Data Engineering· New York, New York, United States

Daniel Ying· Executive Director· Mumbai, Maharashtra, Indiain

Girish Bakhru, M.D.· Executive Director

Henry Yang· Director

Ji Wang· Executive Director· Chinain

Kerrie Swingle· Director of Investor Services

Kevin P. Olsen· Director of Trading Operations· Croton-On-Hudson, New York, United Statesin

Manjot Bhuller· Principalin

Matt Xie, M.D· Director

Priya Malebennur· Director, ESG

Ran Geng· Principal· New York, New York, United Statesin

Ran Geng is a Principal at OrbiMed, where the focus is on investing in biotech companies and healthcare technologies. Areas of investment include treatments for diseases, technologies addressing disparities in healthcare resources, and improvements to healthcare delivery efficiency.

Roy Amariglio, Ph.D.· Principal· United Statesin

Tara Garber· Director· New York, New York, United Statesin

Vicky Qu· Director

Jonathan Mandelbaum· Principal· New York, New Yorkin 𝕏

Jonathan Mandelbaum is a Principal at OrbiMed, a healthcare venture capital firm. He previously worked as a drug discovery scientist and focuses on biotech company formation and medicine development.

Kip Kitur· Principal· New York, New Yorkin

Kip Kitur is a Principal on the Private Equity team at OrbiMed, focusing on healthcare investments. Previously, he worked as a Consultant in The Boston Consulting Group's Healthcare practice in New York and co-founded Sarora Dairies LLC/Ltd, which processes and distributes dairy products in Kenya. He holds a Ph.D. in Pharmacology from Columbia University and a B.A. in Chemistry from Harvard College.

Nate Yee· Principal· New York, New Yorkin

Vivek Sivathanu· Principal· New York, New Yorkin

Sivathanu is a Principal at OrbiMed Advisors, where he invests in biotech, medtech, and diagnostics companies across their development lifecycle. He previously worked as a biotechnology equity research analyst at Evercore ISI and as a management consultant at Simon-Kucher, focusing on drug pricing and commercial strategy in the biopharma and medtech sectors. He holds a Ph.D. in Biomedical Engineering and Technology Commercialization from MIT, with research focused on muscle strength enhancement and personalized medicine approaches in cancer therapy.

Clive Wood, Ph.D.· Venture Partner

Donnie McGrath, M.D., M.P.H.· Venture Partner

Jamie Christensen, Ph.D.· Venture Partner

Jeff Peters· Venture Partner

Mark Rolfe, Ph.D.· Venture Partner

Valerie Odegard, Ph.D.· Venture Partner

Dimitri Krainc· Venture Partner· Chicago, Illinoisin

Iain Dukes· Venture Partner· Philadelphia, Pennsylvaniain

Iain Dukes is a Venture Partner at Orbimed and CEO of Viriom Inc, serving on the executive teams or boards of nine companies across the USA, France, and the UK. His career includes roles as Senior Vice President of Business Development & Licensing at Merck, where he managed licensing deals for Merck Research Laboratories, as well as Vice President of External Research and Development at Amgen, President and CEO of Essentialis Therapeutics, and Vice President of Scientific and Technology Licensing at GlaxoSmithKline. He holds a BSc in Pharmacology from the University of Bath, an MSc in Cardiovascular Studies from the University of Leeds, a DPhil in Physiology and Pharmacology from the University of Oxford, and an MA in Jurisprudence and Law from the University of Oxford.

Kevin Koch· Venture Partner· Boulder, Colorado

Klaus Veitinger· Venture Partner· New York, New Yorkin

Klaus Veitinger joined OrbiMed in 2007 as a Venture Partner, focusing on venture investments in therapeutics, and has held board roles at various OrbiMed portfolio companies. He previously served as CEO of Schwarz Pharma Inc., overseeing its U.S. and Asia businesses through the sale of the Schwarz Group, and spent seven years as a Director of PhRMA. He holds a medical degree and Ph.D. from the University of Heidelberg and an M.B.A. from INSEAD.

Sevgi Gurkan· Venture Partner· San Francisco Bay Areain 𝕏

Sevgi Gurkan joined OrbiMed in 2018 as a Venture Partner. She was previously a founding member of Merck Research Laboratories' South San Francisco Discovery site and a Director in Early Drug Development at MRL. Earlier in her career she was an Associate Professor at Rutgers, Director of the Pediatric Kidney Transplant Program at RWJ University Hospital, and a pediatric nephrologist; she holds a medical degree from Hacettepe University and a Master of Science in Clinical Research from Mount Sinai School of Medicine.

Bill Moschella· Venture Partnerin

Alexander M. Cooper· General Counsel· New York, New York, United States

Andrew P. Kanarek, CFA, CIPM· Chief Risk Officer· New York, New York, United Statesin

Andrew P. Kanarek serves as Chief Risk Officer at OrbiMed Advisors LLC. He works in the investment management industry, with experience spanning equity research, hedge funds, venture capital, asset management, and investment banking. He holds the CFA and CIPM designations.

Bob Smith· Venture Partner· Greater London, England, United Kingdomin

Bob Smith joined OrbiMed in 2024 as a Venture Partner, bringing over thirty years of experience across alliance management, business development, commercial, M&A, and R&D roles. He retired from Pfizer in January 2024, where he led the company's global gene therapy business, its R&D business development activities, and strategic transactions team; he originally joined Pfizer in 2009 through its acquisition of Wyeth, where he led the global M&A group. He holds a B.S. in Neuroscience and an M.B.A. in Finance and Corporate Accounting from the University of Rochester.

C. Scotland Stevens· General Partner and Co-Head of Public Equity· New York, New Yorkin

Scot Stevens is a General Partner and Co-Head of Public Equity at OrbiMed, which he joined in 2005, where he leads trading activities across the firm's business units, geographies, and investment products. Before OrbiMed, he worked in Global Banking & Markets at Goldman, Sachs & Co., trading equity products for healthcare-focused hedge fund clients. He holds an M.B.A. from The Wharton School at the University of Pennsylvania and a B.S. in Business Administration with a minor in Chemistry from the University of North Carolina at Chapel Hill.

Carrie Ma· Controller

Clark Chu· Deputy General Counsel· United States

Daniel Bendlin· Vice President, Technology

Daniel Rhee, CISSP· Chief Technology Officer

Doug Coon· Chief Compliance Officer· New York, New York, United States

Elizabeth Krane· Senior Analyst· New York, New York, United Statesin

Elizabeth Krane is an Analyst at OrbiMed, where she focuses on healthcare investing. She graduated from Southern Methodist University in 2016 with a BA in Economics and a BBA in Finance with a specialization in Alternative Asset Management. During her time at SMU, she served as captain of the varsity swimming team.

Emily Kalenik· Vice President· New York City Metropolitan Areain

Erez Chimovits· Partnerin

Guiyu Zhao, Ph.D.· Vice President

Howell Ma· Associate General Counsel· New York, New York, United Statesin

Jason A. Kahn, CMT· Senior Trader

Jia Sun, Ph.D.· Analyst

Jim Sullivan, Ph.D.· Venture Partner· Greater Chicago Areain

Jim Sullivan joined OrbiMed as a Venture Partner in 2019 and serves as CEO of portfolio company Vanqua Bio, which develops therapeutics for neurological conditions such as Parkinson's disease. He previously was Vice President of Research at AbbVie, overseeing research across oncology, immunology, neurology, hepatitis C, and cystic fibrosis, and has advanced more than 100 compounds into clinical development. He holds a bachelor's degree and Ph.D. in biochemistry from Trinity College Dublin, completed postdoctoral research in neurobiology at Northwestern University, and is an adjunct faculty member there.

Joseph N. Kleeman· Senior Trader· San Francisco, California, United States

Joshua Golomb· Partner· New York, New York, United Statesin

Joshua Golomb is a partner at OrbiMed Advisors, where he focuses on investments in therapeutics. His expertise spans global pharmaceuticals, specialty pharmaceuticals, and biotech.

Judy Liu· Deputy Chief Compliance Officer

Kamran Elahi· Senior Associate· New York, New York, United Statesin

Kirsten Kearns· Global Head of Human Resources· New York, New York, United States

Lauren Ralph· Senior Associate

Madeline Huber· Vice President· New York, New York, United Statesin

Mark R. Jelley· Partner· New York, New Yorkin

Michael Eggenberg· Partner· United Statesin

Scott Winer· Controller· New York, New York, United States

Steve Pearn· Senior Controller

Sumona Chakraborty· Executive Director· New York, New York, United Statesin

Sumona Chakraborty is an Executive Director on OrbiMed's Asia private equity team, which she joined in 2018. Before OrbiMed, she worked in investment banking at Avendus Capital, and earlier at Equirus Capital and UBS. She holds a Bachelor of Technology in Biotechnology from the National Institute of Technology, Warangal and an M.B.A. from S.P. Jain Institute of Management and Research, Mumbai.

Trey Block· Chief Financial Officer

Xavier Cheng, Ph.D.· Analyst

Zack Mager· Vice President· New City, New York, United Statesin

Anat Nursella· Venture Partner· Israelin

Brendan Weber· Principal· Hoboken, New Jerseyin

Jessica Zhang· Vice President· Boston, Massachusetts

Lars Enstrom· Managing Director· New York, New Yorkin

Natasha Shervani· Vice President· New York, New Yorkin

William Price· Managing Director· New York, New Yorkin

Founder mafia

The OrbiMed mafia →

14 people who came through OrbiMed went on to found or lead other companies.

Iain DukesVenture PartnerFounded Lomondther +5 Peter ThompsonGeneral PartnerFounded Cleave Biosciences +4 Matthew R. PattersonEntrepreneur-In-ResidenceFounded Audentes Therapeutics +2 Tadd WesselPartnerFounded Petrichorcap +1 Sheila GujrathiVenture AdvisorFounded Prana Therapies +1 Kevin KochVenture PartnerFounded Edgewise Therapeutics +1 Badreddin EdrisPrivate Equity Vice PresidentFounded Silverback Therapeutics +1 Mikael DolstenPrivate Equity PartnerFounded Quarry Thera Steven YeciesConsultantFounded Javelin Oncology Sevgi GurkanVenture PartnerFounded Perfuse Therapeutics Stephen SquintoExecutive PartnerFounded Alexion Pharmaceuticals Jim Sullivan, Ph.D.Venture PartnerFounded Vanqua Bio

+ 2 more →

What they invest in

from 279 of 338 portfolio companies

Biotech ×213Healthtech ×179Medical Devices ×91Digital Health ×48AI & Machine Learning ×38Deep Tech ×28Hardware ×17Advanced Manufacturing ×10

HQs:United States×182China×11India×11Switzerland×3United Kingdom×3Australia×1

Who they back

founder profiles across 101 portfolio companies

40%

solo founders

40 of 101 mapped founding teams

26%

repeat founders

of 85 founders with career history

~4 yrs

old at investment

median across 64 dated deals

Founding team size:solo founder×402 founders×343 founders×154+ founders×12

Where their founders studiedfrom 78 founders with education data

Massachusetts Institute of Technology ×5Stanford University ×4Harvard Medical School ×3MIT Sloan School of Management ×3Princeton University ×3Stanford University School of Medicine ×3University of California, Berkeley ×3Ben-Gurion University of the Negev ×2

What their founders studiedfrom 81 founders with field-of-study data

Life Sciences ×27Medicine ×20Engineering ×15Chemistry ×13Business & Management ×12Computer Science ×8Finance & Accounting ×4Physics ×3

Where their founders worked beforefrom 85 founders with career history

Stanford University ×4Atlas Venture ×3Dana-Farber Cancer Institute ×3Harvard Medical School ×3Aisling Capital ×2ARCH Venture Partners ×2GlaxoSmithKline ×2M.D.G Medical Ltd. ×2

Accelerator rootsportfolio companies that came through a program

Y Combinator ×2

46 founders hold a PhD · 12 hold an MBA (of 87 with degree data) · backed the same founder in 2+ companies: 4 founders

Investments · 338 tracked

founders shown can be your intro path

By year:2026 · 10 2025 · 25 2024 · 12 2023 · 9 2022 · 8 2021 · 21 2020 · 11 2019 · 16 2018 · 9 2017 · 7 2016 · 9 2015 · 12161 dated

Q32 Bioq32bio.com in 𝕏NASDAQ: QTTBSeries A · May 2020 · $46M✓ verified

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.

BiotechHealthtech

Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)in David Appugliese(Senior Vice President, Head of People)in

Co-investorsAtlas Venture Agent Capital CU Healthcare Innovation Fund OUP (Osage University Partners)Sanofi Ventures 5AM Ventures +2 more

Scribe Therapeuticsscribetx.com in 𝕏NASDAQ: SCTXMar 2021✓ verified

Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.

BiotechDeep TechHealthtechMedical DevicesBerkeley, US

Benjamin Oakes(Founder)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)Brett Staahl(Founder)

Co-investorsAndreessen Horowitz Avoro Capital Advisors Menlo Ventures RA Capital Wellington Management

Sionna Therapeuticssionnatx.com in 𝕏NASDAQ: SIONSeries B · Apr 2022 · $110M✓ verified

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.

BiotechHealthtechMedical Devices

Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)

Co-investorsAtlas Venture RA Capital Viking Global

Upstream Bioupstreambio.com in 𝕏NASDAQ: UPB✓ verified

Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.

BiotechHealthtechWaltham, US

Rand Sutherland(Chief Executive Officer)in Allison Ambrose(General Counsel)in Aaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in

Co-investorsAccess Industries Access Biotechnology Bain Capital Life Sciences Decheng Capital HBM Healthcare Investments HBM Partners +5 more

Aadi Bioscienceaadibio.com inNASDAQ: WHWKMar 2017SEC filingmedium confidence

Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.

BiotechHealthtechMorristown, US

Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)

Board seatChau Khuong· per SEC Form D · $41.8M raise · filed Mar 2017

Co-investors3B Future Health Fund Ally Bridge Group Decheng Capital Vivo Capital

Adicet Bioadicetbio.comNASDAQ: ACETAug 2015

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in

Board Carl Gordon(Director)inFlorent Gros(Director)

Board seat Jonathan Silverstein Carl L. Gordon· per SEC Form D

Co-investorsForesite Capital Pontifax Venture Capital Quan Capital aMoon Novartis Venture Fund PureTech Health

Arvinas Holding Co. LLCarvinas.com in 𝕏NASDAQ: ARVNOct 2015SEC filingmedium confidence

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.

BiotechHealthtechNew Haven, US

Sean Cassidy(Executive Officer)in Manuel Litchman(Executive Officer, Director)in Randy Teel(President and Chief Executive Officer; Director)inCraig Crews(Founder)

Board Liam Ratcliffe(Director)in

Board seat Stephen Squinto· per SEC Form D · $55M raise · filed Apr 2018

Co-investors5AM Ventures Access Biotechnology Canaan Partners Connecticut Innovations Nextech Invest RA Capital +2 more

Calcimedicacalcimedica.com in 𝕏NASDAQ: CALCJul 2019

CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.

BiotechHealthtechLa Jolla, US

Kenneth A. Stauderman(Co-founder)inGonul Velicelebi(Co-founder)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Michael J. Dunn(Executive Officer)inStephen Bardin(Chief Financial Officer)in

Board seatChau Khuong· per SEC Form D

Co-investorsAisling Capital MESA VERDE VENTURE PARTNERS Revelation Partners Sanderling Ventures Clarus Ventures

Compass Therapeuticscompasstherapeutics.com in 𝕏NASDAQ: CMPXJun 2020

Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.

BiotechHealthtechCambridge, US

Schuetz Thomas(Executive Officer, Director)in Errik Anderson(Executive Officer, Director)in Thomas J. Schuetz(Executive Officer, Director)in Vered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)in Neil Lerner(Senior Vice President, Chief Accounting Officer)in

Board seat Stephen Squinto Carl L. Gordon· per SEC Form D

Co-investorsAlumni Ventures BioBrit F-Prime Capital Foresite Capital GV (Google Ventures)venBio Partners +3 more

ImaraNASDAQ: ELVNSeries B · Mar 2019 · $63Macquired by Enliven Therapeutics · Feb 2023

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Board seat David Bonita· per SEC Form D

Co-investorsBay City Capital New Enterprise Associates (NEA)Pfizer Venture Investments RA Capital Alexandria Arix Bioscience +3 more

Keros Therapeuticskerostx.com inNASDAQ: KROSMar 2020

Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.

BiotechHealthtechLexington, US

Jasbir Seehra(Co-Founder, Chief Executive Officer and Director)in

BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in

Board seat Carl L. Gordon· per SEC Form D

Co-investorsArkin Capital Foresite Capital Pontifax Venture Capital

Mirna Therapeuticsblogmedicina.com 𝕏OTC: SYBXJun 2019SEC filingmedium confidence

A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.

BiotechMedia & EntertainmentAustin, US

Matthew Winkler(Director)Sinil Kim(Executive Officer)in Paul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)

BoardMichael Powell(Director)

Board seatChau Khuong· per SEC Form D · $80M raise · filed Jun 2019

Co-investorsNew Enterprise Associates (NEA)Pfizer Venture Investments Correlation Ventures OUP (Osage University Partners)Pfizer Ventures Sofinnova Ventures

NextCurenextcure.comNASDAQ: NXTCDec 2015

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)in Udayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)in Sourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in

Board seatChau Khuong· per SEC Form D

Co-investorsBay City Capital Canaan Partners LAV Lilly Asia Ventures Pfizer Venture Investments Quan Capital +4 more

Prelude Therapeuticspreludetx.com in 𝕏NASDAQ: PRLDJun 2016

Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors.

BiotechHealthtechNewark, US

Krishna Vaddi(Executive Officer, Director)

BoardPaul Friedman(Director of Issuer)

Board seat David Bonita· per SEC Form D

Co-investorsThe Innovation Space

SI-BONEsi-bone.comNASDAQ: SIBNJun 2016SEC filingmedium confidence

SI-BONE develops medical devices for treating sacroiliac (SI) joint dysfunction and chronic low back pain, targeting patients and physicians.

HealthtechMedical DevicesSan Jose, US

Mark Reiley(Director)inJeffrey W. Dunn(Executive Officer, Director)Robert E. Johnson(Executive Officer)Dan Murray(Executive Officer)Laura A. Francis(Chief Executive Officer)

BoardTimothy E. Davis(Director)

Board seat David Bonita· per SEC Form D · $21M raise · filed Jun 2016

Co-investorsArboretum Ventures Montreux Equity Partners

Spruce Biosciencessprucebiosciences.com in 𝕏NASDAQ: SPRBFeb 2020SEC filingmedium confidence

Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).

BiotechHealthtechSouth San Francisco, US

Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg(Chief Executive Officer)in

BoardSimpson Camilla(Director)Tiba Aynechi(Director)in Bali Muralidhar(Director)in

Board seat Dina Chaya· per SEC Form D · $53.6M raise · filed Feb 2023

Co-investorsAisling Capital HealthCap RiverVest Venture Partners Abingworth Norwest Venture Partners Novo Holdings +1 more

Synlogicsynlogictx.com in 𝕏OTC: SYBXMay 2017SEC filingmedium confidence

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Bharatt Chowrira(Executive Officer)inMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)in Paul Miller(Executive Officer)inAoife Brennan(Executive Officer)inTodd Shegog(Executive Officer)in

Board seatChau Khuong· per SEC Form D · $42M raise · filed May 2017

Co-investorsAtlas Venture CLI Ventures New Enterprise Associates (NEA)NSG Ventures Pfizer Venture Investments Sofinnova Ventures +1 more

Adagio TherapeuticsNASDAQ: IVVDApr 2021 · $336M

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Co-investorsGV (Google Ventures)Fidelity Investments Foresite Capital Mithril Capital Management Omega Funds Polaris Partners +3 more

Adaptive Biotechnologiesadaptivebiotech.com in 𝕏NASDAQ: ADPT

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US

Chad Robins(Chief Executive Officer, Co-founder, Chairman of the Board)in Harlan Robins(Co-founder; Chief Scientific Officer until 2026)in Kathleen Determann(Executive Officer)inDean Schorno(Executive Officer)inChris Carlson(Executive Officer)Kyle Piskel(Chief Financial Officer)in

Co-investorsDecheng Capital FMG Capital Foresite Capital Khosla Ventures Viking Global Casdin Capital

Alumisalumis.com in 𝕏NASDAQ: ALMS

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)in Jack Danilkowicz(Chief Commercial Officer)in Jörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in

Co-investorsForesite Capital HBM Healthcare Investments HBM Partners Nextech Invest Samsara BioCapital SR One Capital Management +3 more

Aura Biosciencesaurabiosciences.com in 𝕏NASDAQ: AURA

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsAdvent Life Sciences Chiesi Ventures Columbus Venture Partners Droia Ventures Foresite Capital Jazzya Investments +6 more

Avita Medicalavitamedical.com in 𝕏NASDAQ: RCELNov 2019

RECELL is an FDA-approved autologous skin cell suspension device for treating burns, trauma, and surgical wounds by harvesting a patient's own skin cells and applying them to accelerate healing and reduce the need for large skin grafts.

BiotechHealthtechMedical DevicesMelbourne, US

Fiona Wood Dale A Sander(Executive Officer)in Cary Vance(Executive Chairman & Interim Chief Executive Officer)in

BioAge Labsbioagelabs.com in 𝕏NASDAQ: BIOAFeb 2024

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Founder)in Eric Morgen(Founder)inDov Goldstein(Executive Officer)in

Board Patrick Enright(Director)in

Co-investorsAndreessen Horowitz Elad Gil Felicis Ventures Green Sands Equity IA Seed Ventures Longitude Capital +19 more

Biomxbiomx.com in 𝕏NYSE: PHGE

BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.

AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardwareNess Ziona

Jonathan Solomon(Chief Executive Officer)inMerav Bassan(Chief Development Officer)in Marina Wolfson(Chief Financial Officer)inJesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)

Co-investorsAMR Action Fund Baruch Future Ventures NSG Ventures SBI JI Innovation Advisory Ltd.Seventure Partners 8VC +2 more

Caris Life Sciencescarislifesciences.com in 𝕏NASDAQ: CAIOct 2020 · $240M

Caris Lifesciences operates a precision oncology platform that analyzes DNA, RNA and proteins across tissue and blood to profile a patient's cancer and match treatments and clinical trials.

AI & Machine LearningBiotechHealthtech

David Dean Halbert(Chairman, Founder and CEO)

Co-investorsCoatue Management Silver Lake Partners Sixth Street Braidwell Millennium Management

Crinetics Pharmaceuticalscrinetics.com in 𝕏NASDAQ: CRNX

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)Stephen Betz(Chief Scientific Officer)in R. Scott Struthers(President, Chief Executive Officer and Director)in Tobin Schilke(Chief Financial Officer)in Isabel Kalofonos(Chief Commercial Officer)inYunFei Zhu(Executive Officer)

Co-investors5AM Ventures Foresite Capital RA Capital Vivo Capital

Cullinan Therapeuticscullinantherapeutics.com 𝕏NASDAQ: CGEM

Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.

BiotechHealthtechMedical Devices

Mary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)Jennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)in Nadim Ahmed(President and Chief Executive Officer)in

Co-investorsForesite Capital Nextech Invest Biotechnology Value Fund

CytomX Therapeuticscytomx.com in 𝕏NASDAQ: CTMX

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.

BiotechHealthtechSouth San Francisco, US

Sean A. McCarthy(Chief Executive Officer and Chairman)inMarcia P. Belvin(SVP, Chief Scientific Officer)inDawn Benson(SVP, Quality and Product Manufacturing)inWayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)in Chris Ogden(Chief Financial Officer)in

Co-investorsATEL Ventures Canaan Partners Longitude Capital Pfizer Venture Investments Wellington Management Third Rock Ventures

Damora TherapeuticsNASDAQ: DMRA

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

Garrett Winslow(Executive Officer)in Lori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Co-investorsAccess Biotechnology Viking Global Andreessen Horowitz BAM Elevate Bay City Capital Commodore Capital +8 more

DarioHealthdariohealth.com in 𝕏NASDAQ: DRIOJun 2022 · $50M

Dario provides digital tools and support to help people manage chronic conditions such as diabetes between provider visits.

BiotechDigital HealthHealthtechMental HealthWellness & FitnessNew York, US

Oren Fuerst, PhD(Director)Erez Raphael(Chief Executive Officer)in Zvi Ben David(Chief Financial Officer, Treasurer, and Secretary)inSteven Nelson(Chief Commercial Officer)inGadi Levin(Executive Officer, Director)in

BoardAdam K. Stern(Director)

Co-investorsAgate Medical Investments LP Leo Capital Ventures Pitango

Disc Medicinediscmedicine.com in 𝕏NASDAQ: IRONSep 2021 · $90M

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)in Jean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)in Pamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in

Co-investorsAccess Biotechnology Atlas Venture Bain Capital Life Sciences Foresite Capital Frazier Life Sciences 5AM Ventures +7 more

Edgewise Therapeuticsedgewisetx.com in 𝕏NASDAQ: EWTX

Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

BiotechDigital HealthBoulder, US

Kevin Koch(Executive Officer, Director)in Alan Russell(Director)in Badreddin Edris(Director and Co-Founder)in Kenneth Harrison(Director)

Board Peter Thompson(Director)in Jonathan Root(Director)in

Co-investorsBoulder Ventures Foresite Capital US Venture Partners Viking Global Wellington Management Deerfield Management Company +1 more

Emergent Biosolutionsemergentbiosolutions.com in 𝕏NYSE: EBSOct 2018

Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic.

Advanced ManufacturingBiotechHealthtechGaithersburg, US

Fuad El-Hibri(Director, Executive Officer)in Robert G Kramer(Executive Officer)inKatherine Strei(Executive Officer)Adam R Havey(Executive Officer)inDaniel J Abdun-Nabi(Executive Officer, Director)inJoseph C. Papa(President, CEO and Director)

Co-investorsAdvent Life Sciences

Enliven Therapeuticsenliventherapeutics.com inNASDAQ: ELVN

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)in Ben Hohl(Chief Financial Officer and Head of Corporate Development)in

Co-investors5AM Ventures Pfizer Venture Investments Roche Venture Fund ARCH Venture Partners Bay City Capital Janus Henderson Investors +2 more

Forte BiosciencesNASDAQ: FBRX

Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody intended to treat autoimmune diseases including celiac disease, vitiligo, alopecia areata, and type 1 diabetes by modulating immune cell activity.

BiotechSherman Oaks, US

Paul A. Wagner(Chairman, President, Chief Executive Officer and Director)inAntony A. Riley(Chief Financial Officer)inTuan Huynh(Director)Lawrence Eichenfield(Director)

Insmedinsmed.com in 𝕏NASDAQ: INSM

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

Will Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSara Bonstein(Chief Financial Officer)inRoger Adsett(Chief Operating Officer)Martina Flammer(Chief Medical Officer)in S. Nicole Schaeffer(Chief People Strategy Officer)in

Co-investorsBessemer Venture Partners F-Prime Capital Foresite Capital Hercules Capital, Inc.Prospect Venture Partners Ridgeback Capital +1 more

InspireMDinspiremd.comNASDAQ: NSPRJul 2025 · $58M

InspireMD develops and commercializes medical devices for vascular intervention, including carotid stent systems and embolic protection systems sold through direct sales in the United States and via distributors in international markets.

BiotechHealthtechMiami, US

Patrick Verta(Executive Officer)inPete Ligotti(Executive Officer)inMike Lawless(Chief Financial Officer)Shane Gleason(Executive Officer)in Marvin Slosman(President and Chief Executive Officer)inAndrea Tommasoli(Chief Operating Officer)

Intellia Therapeuticsintelliatx.com in 𝕏NASDAQ: NTLAAug 2015

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)in John Leonard(President and Chief Executive Officer)in James Basta(Executive Vice President, General Counsel and Corporate Secretary)in Edward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsage1 Atlas Venture Avoro Capital Advisors EcoR1 Capital Foresite Capital Ridgeback Capital +1 more

Invivydinvivyd.com in 𝕏NASDAQ: IVVD

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsBain Capital Life Sciences Foresite Capital MRL Ventures Fund Premji Invest RA Capital GV (Google Ventures)+2 more

NeuroPaceneuropace.com in 𝕏NASDAQ: NPCEAug 2020

NeuroPace is a commercial-stage medical device company that develops the RNS System, a brain-responsive neurostimulation platform delivering real-time treatment at the seizure source for patients with drug-resistant epilepsy and other brain disorders.

Digital HealthHardwareHealthtechMedical DevicesMountain View, US

Rebecca Kuhn(Executive Officer)inFrank Fischer(Executive Officer, Director)Joel Becker(President, Chief Executive Officer and Director)inVince Burgess(Director)in Renee Ryan(Director)inRay Larkin(Director)

Co-investorsAccelmed Partners New Enterprise Associates (NEA)

Oncology InstituteNASDAQ: TOI

The Oncology Institute operates a national network of 65 affiliated physician clinics and contracts with independently-owned oncology and hematology practices to deliver outpatient cancer care through fee-for-service arrangements and value-based contracts that shift financial risk to the company.

HealthtechCerritos, US

Robert Carter(Executive Officer)Jeremy Castle(Executive Officer)Daniel Virnich(Executive Officer, Director)Yale Podnos(Executive Officer)inBrad Hively(Director)Mihir Shah(Executive Officer)in

Onconova Therapeutics inNASDAQ: TRAW

Traws Pharma (formerly Onconova Therapeutics) develops investigational antiviral agents targeting respiratory viral infections and certain cancers, with four clinical-stage programs including a cap-dependent endonuclease inhibitor for influenza and bird flu, a protease inhibitor for COVID-19, and two kinase inhibitors for solid tumors and blood cancers.

BiotechNewtown, US

Ramesh Kumar, Ph.D(Executive Officer, Director)E. Premkumar Reddy(Director)Manoj Maniar(Executive Officer)inThomas McKearn(Executive Officer)Ajay Bansal(Executive Officer)in Steven Fruchtman(Executive Officer)in

ORIC Pharmaceuticalsoricpharma.com inNASDAQ: ORIC

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

Richard Heyman(Chairman, Founder, Scientific Advisory Board)in Charles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)in Pratik Multani(Chief Medical Officer)inJacob Chacko(President, Chief Executive Officer and Board Member)in

Co-investorsEcoR1 Capital New Enterprise Associates (NEA)Nextech Invest Taiho Ventures, LLC The Column Group Viking Global

Passage Biopassagebio.com in 𝕏NASDAQ: PASGAug 2019 · $110M

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in

Board Patrick Heron(Director)in Carl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Co-investorsFrazier Life Sciences Access Biotechnology Frazier Healthcare Partners Lilly Asia Ventures New Leaf Venture Partners Sphera Funds Management +2 more

Relmada Therapeuticsrelmada.comNASDAQ: RLMDMar 2026 · $160M

Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.

BiotechHealthtechNew York, US

Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)in Eliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)

Co-investorsBioAdvance BAM Elevate Braidwell Commodore Capital Janus Henderson Investors RA Capital +2 more

Shattuck Labsshattucklabs.com inNASDAQ: STTK

Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases.

BiotechHealthtechAustin, US

Josiah Hornblower(President/CEO)inTaylor(Co-founder & Chief Executive Officer, Board Member)

BoardWalter Loewenbaum(Director)

Co-investorsEcoR1 Capital Hatteras Venture Partners Rocky Point Ventures REDMILE T. Rowe Price

Sonendosonendo.comOTC: SONXJun 2013

Sonendo is a medical technology company that develops and manufactures the GentleWave System, a technology platform for treating tooth decay by cleaning and disinfecting the interior spaces of teeth without removing tooth structure.

HardwareHealthtechMedical DevicesLaguna Hills, US

Bjarne Bergheim(Executive Officer, Director)in John McGaugh(Executive Officer)inJohn Bostjancic(Executive Officer)Hugh Neuharth(Executive Officer)Roy T. Chen(Chief Talent Officer)Chris Guo(Interim Chief Financial Officer)in

Co-investorsEssex Woodlands Healthcare Partners Fjord Ventures General Atlantic Meritech Capital Partners Neomed Management Pura Vida Investments +1 more

TELA Biotelabio.com in 𝕏NASDAQ: TELA

Offers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.

BiotechMalvern, US

Antony Koblish(Founder)inFrancis Conway(Executive Officer)Maarten Persenaire(Executive Officer)Christine Arasin(Executive Officer)

Board Kevin Rakin(Director)inAshley Freidman(Director)

Co-investorsCheckmate Capital Group LLC Essex Woodlands Healthcare Partners HighCape Capital Signet Healthcare Partners 1315 Capital RTW Investments L.P.

Trawspharmatrawspharma.comNASDAQ: TRAW

Traws Pharma is a pharmaceutical company developing therapeutics, with a leadership focus spanning oncology, infectious disease, and medical science areas.

BiotechHealthtech

Iain Dukes(Chief Executive Officer)inCharles Parker(Chief Financial Officer)C. David Pauza, PhD(Chief Science Officer)Robert R. Redfield, MD(Chief Medical Officer)Victor Moyo, MD(CMO Oncology)Nikolay Savchuk, PhD(Chief Operating Officer)

Verastemverastem.com in 𝕏NASDAQ: VSTM

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)in CATHY CAREW(Executive Officer)in JONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in

Co-investorsBessemer Venture Partners Cardinal Partners Foresite Capital Lightstone Ventures Longwood Fund Oberland Capital +1 more

Verricaverrica.com in 𝕏NASDAQ: VRCA

Verrica Pharmaceuticals is a therapeutics company developing and commercializing treatments for dermatological diseases, including molluscum contagiosum, common warts, and skin cancers such as basal cell and squamous cell carcinoma.

BiotechHealthtechMedical DevicesWest Chester, US

Noah Rosenberg(Executive Officer)inJohn Kirby(Executive Officer)Matthew Davidson(Executive Officer, Director)

Board Jayson Rieger(Executive Officer, Director)in Paul B. Manning(Director)in David Zawitz(Executive Officer)

Co-investorsPBM Capital

Alpheus Medicalalpheusmedical.com inMay 2025✓ verified

Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.

BiotechHealthtechMedical DevicesChanhassen, US

Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)

Board Imran Eba(Executive Officer)in

Board seat Klaus Veitinger· per SEC Form D

Co-investorsHealthQuest Capital Samsara BioCapital SV Health Investors Action Potential Venture Capital Ltd.BrightEdge

Perfuse Therapeuticsperfusetherapeutics.com inMar 2019✓ verified

Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.

BiotechHealthtechMedical DevicesSan Francisco, US

Sevgi Gurkan(Founder, Chief Executive Officer, and Member of the Board of Directors)in

BoardChristy Shaffer(Director)

Board seatChau Khuong· per SEC Form D

Co-investorsAccess Biotechnology Catalio Capital Management, LP Hatteras Venture Partners LAV Lilly Asia Ventures Hatteras

ADARx Pharmaceuticalsadarx.com inSeries B · Sep 2021 · $75M✓ verified

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical DevicesSan Diego, US

Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)in Robert A. MacLeod(Chief Scientific Officer)in Christopher Claeboe(Senior Vice President of Operations)in

Co-investorsBain Capital Life Sciences SR One Capital Management Lilly Asia Ventures T. Rowe Price Ascenta Capital TCG Crossover +3 more

Aer Therapeuticsaertherapeutics.com in✓ verified

Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma.

BiotechHealthtechMedical DevicesRaleigh, US

Thomas Mathers(Executive Officer, Director)inJames Shaffer(Executive Officer, Director)John Fahy(Director)in

Board Christy Shaffer(Director)in Rishi Gupta(Director)in Tim Shannon(Director)in

Co-investorsHatteras Venture Partners Canaan Partners Pappas Capital

Alentis Therapeuticsalentis.ch in✓ verified

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.

AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH

Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)in Luigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in

Co-investorsAvego BioScience Capital BioMedPartners Frazier Life Sciences Jeito Capital Longitude Capital Novo Holdings +5 more

Aspen Neuroscienceaspenneuroscience.com in 𝕏Seed · Apr 2020 · $70M✓ verified

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)

Co-investorsARCH Venture Partners Lifeforce Capital Domain Associates EDB Investments Section 32 Frazier Life Sciences +9 more

Brenigbrenigther.com in 𝕏✓ verified

Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery.

AI & Machine LearningBiotechHealthtechDover, US

Megan McGill(Chief Executive Officer)in Iain Dukes(Chief Business Officer / Chairman of the Board)in Nikolay Savchuk(Chief Operating Officer)Tien Dam(Chief Medical Officer)in

Co-investorsNew Enterprise Associates (NEA)BGV Torrey Pines Investment

Congruence Therapeuticscongruencetx.com inSeries A · Feb 2022 · $50M✓ verified

Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.

AI & Machine LearningBiotechDeep Tech

Clarissa Desjardins(Founder)in

Co-investorsAlexandria DIMENSION Angelini Ventures BDC Thrive Venture Fund for Women Lumira Ventures Amplitude Venture Capital +1 more

Corteria Pharmaceuticalscorteriapharma.com in✓ verified

Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.

BiotechDigital HealthHealthtechLongevity

Philip Janiakin Marie-Laure Ozoux inRégis OlivierinFrancesca C. LawsonMark KowalaEleonore Jouannyin

Co-investorsFountain Healthcare Partners Jeito Capital Kurma Partners V-Bio Ventures Omnes Capital Invivo Capital Partners +1 more

Entero Healthcareenterohealthcare.com in✓ verified

Entero Healthcare Solutions is a healthcare products distribution company operating in India, connecting pharmaceutical manufacturers with pharmacies and healthcare providers.

HealthtechLogistics & Supply Chain

Prem Sethi(Promoter, Whole-time Director & COO)in Prabhat Agrawal(Promoter, Managing Director & CEO)in

Enyo Pharmaenyopharma.com in 𝕏Series B · Jun 2018 · $47M✓ verified

Enyo Pharma is a biotechnology company focused on drug development in the life sciences and therapeutics field.

BiotechHealthtechMedical DevicesLyon, FR

Jacky Vonderscher(Co-founder & CEO)inLaurène Meyniel-Schicklin(Founder, Head of Bioinformatics)in Benoît de Chassey(Founder, Head of Drug Discovery Platform)inPatrice André(Founder, Medical Advisor)inVincent Lotteau(Founder, Advisor)Jean-Jacques Garaud(Co-founder)in

Co-investorsAndera Partners Sofinnova Partners Bpifrance

Forward Txforward-tx.com in✓ verified

Forward Therapeutics develops oral small-molecule medicines targeting inflammation-driven diseases, using a structure-based, data-driven discovery engine to design drugs against validated pathways.

AI & Machine LearningBiotech

Co-investorsCurie.Bio

Frontera Therapeuticsfronteratherapeutics.com in✓ verified

Frontera Therapeutics is a biotechnology company engaged in therapeutic research and development, spanning translational medicine, clinical operations, and manufacturing.

BiotechDeep TechHealthtechBoston, US

Xinyan Li(CEO)

Co-investorsBoyu Capital Creacion Ventures HongShan Capital Group 6 Dimensions Capital

GentiBiogentibio.com in 𝕏Aug 2020✓ verified

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.

BiotechHealthtechMedical Devices

Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)inDavid Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)inTom Wickham(Chief Scientific Officer)

Co-investorsNovartis Venture Fund JDRF T1D Fund RA Capital

Gracellbiogracellbio.com in✓ verified

Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.

BiotechHealthtechMedical DevicesSuzhou, CN

William Wei Cao in

Co-investorsLAV Lilly Asia Ventures Pivotal Life Sciences Exome Asset Management Janus Henderson Investors RA Capital +3 more

i2020 Acceleratori2020accelerator.com inApr 2021✓ verified

i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.

BiotechDeep TechHealthtechSan Diego, US

Co-investorsTorrey Pines Investment BioGeneration Ventures BGV

Iecureiecure.com✓ verified

iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children.

BiotechHealthtechMedical Devices

James M. Wilson(Scientific Founder)Joseph Truitt(CEO & Board Member)inPaul Firuta(COO)inAlex Monteith(Chief Business Officer)David Garrett(CFO)in Gabriel M. Cohn(Chief Medical Officer)in

Co-investorsLYFE Capital Versant Ventures

Insilico Medicineinsilico.com in 𝕏Sep 2019✓ verified

Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development.

AI & Machine LearningBiotechDigital HealthHealthtechHong Kong, US

Aleksandrs Zavoronkovs(Executive Officer, Director)Alex Zavoronkov(Director)Alex Zhavoronkov(Founder)inAlex Aliper(President)inFeng Ren(Chief Scientific Officer, Executive Director & Co-CEO)in

Board Nisa Leung(Director)in

Co-investorsLilly Asia Ventures Qiming Venture Partners Warburg Pincus Baidu Ventures Eight Roads Ventures Lake Bleu Capital +13 more

Lattice MedTechlatticemedtech.com in✓ verified

Lattice Medtech distributes medical devices and offers strategic manufacturing and full-service distribution partnerships for medical device companies.

HealthtechLogistics & Supply ChainMedical Devices

Rahul Garg(CEO & Founder)Rahul Bagaria(CFO)

Mdclonemdclone.com in 𝕏Mar 2022✓ verified

MDClone provides a healthcare data platform that uses synthetic data to support clinical research and care-improvement initiatives, used by health systems such as Intermountain for programs targeting chronic conditions like kidney disease, diabetes, and cardiovascular disease.

AI & Machine LearningData & InfrastructureDigital HealthHealthtech

Ziv Ofek(Co-Founder and President)in Bruno Lempernesse(Chief Executive Officer)inAaron Galaznik(Chief Medical Officer)in Almog Ohayon(Chief Product and Technology Officer)in

Co-investorsaMoon Lightspeed Venture Partners Warburg Pincus Declaration Partners Viola Ventures

MinervaXminervax.com inOct 2023✓ verified

MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.

BiotechHealthtech

PerBengt(CSO)

Co-investorsAdjuvant Capital Industrifonden Pureos Bioventures Sanofi Ventures Sunstone Capital EQT Life Sciences +2 more

Oncusp Therapeuticsoncusptx.com inSeries A · Jan 2024 · $100M✓ verified

OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.

BiotechMedical DevicesNew York, US

Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)Bing Yuan, Ph.D., MBA(Co-Founder, Chief Executive Officer)Eric Slosberg, Ph.D.(Co-Founder, Chief Development Officer)Andy Fu, PharmD, MBA(Co-Founder, Chief Business Officer)

Co-investorsCatalio Capital Management, LP F-Prime Capital Sofinnova Ventures De Novo Ventures Insight Partners NVIDIA

Ottimo Pharmaottimopharma.com inSeries A · Dec 2024 · $140M✓ verified

Ottimo is a biotech company developing oncology and immuno-oncology therapeutics, including antibody-based cancer treatments.

BiotechHealthtech

Jonny Finlay(Founder and Chief Scientific Advisor)David Epstein(Chair & Chief Executive Officer)inMehdi Shahidi(Head of Development & Chief Medical Officer)Ling Zeng(General Counsel and EVP of Execution)inSpencer Fisk(Chief Technical and Quality Officer)

Co-investorsMedicxi Samsara BioCapital Avoro Capital Advisors JMI Equity

Quantxbioquantxbio.com in✓ verified

QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates.

AI & Machine LearningBiotechDeep Tech

Co-investorsSanofi Ventures Creacion Ventures Lilly Asia Ventures

Sirius Therapeuticssiriusrna.com✓ verified

Sirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area.

BiotechHealthtechLongevityMedical DevicesSan Diego, US

Qunsheng Ji(Chief Executive Officer)Curt Bradshaw(Chief Scientific Officer)Patrick Yue(Chief Medical Officer)Hailei Lu(Chief Financial Officer)

Co-investorsDelos Capital Creacion Ventures

Uquifauquifa.com in✓ verified

Uquifa is a supplier of active pharmaceutical ingredients and related products for the human and animal health markets, emphasizing quality standards and regulatory compliance.

Advanced ManufacturingBiotechHealthtechNew MaterialsBarcelona, ES

Saurabh Gurnurkar(Managing Director & CEO, Uquifa Group)inPilar Valle(Chief Financial Officer)inAlfred Pascual(Corporate Manufacturing Operations Director)inPéter Ács(General Manager & Chief Operating Officer – Soneas Chemicals Ltd.)

Variantyxvariantyx.com inFeb 2021✓ verified

Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.

AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US

Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)in Jeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))in Christine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in

Co-investors20/20 HealthCare Partners LLC Bosch Ventures New Era Capital Partners Peregrine Ventures Pitango Quark Venture Inc.+2 more

Whale Imagingwhaleimaging.com in 𝕏✓ verified

Whale Imaging is a medical imaging company.

HardwareHealthtechMedical DevicesBoston, US

Sean Z.(Founder)in

Co-investorsSequoia Capital

Acutus Medicalacutusmedical.comJun 2022

HealthtechCarlsbad, US

Christoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVince Burgess(Director)inJohn Dahldorf(Executive Officer)

BoardAditya Puri(Director)

Board seat David Bonita· per SEC Form D

Co-investorsAdvent Life Sciences Xeraya Capital Deerfield Management Company Formation Group GE Ventures Index Ventures

Adelaadelabio.com in 𝕏Apr 2026

Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)in Anne-Renee Hartman(Founder)inAlan Williams(Executive Officer)in Lisa Alderson(Executive Officer, Director)inPriscilla Huang(Executive Officer)in

Board seat David Bonita· per SEC Form D

Co-investorsDecheng Capital F-Prime Capital Deerfield Management Company Menlo Ventures

Aerpio Therapeuticsaerpio.comMar 2016

BiotechCincinnati, US

Robert Shalwitz(Executive Officer)Joseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)Ian A.W. Howes(Executive Officer)

Board seatChau Khuong· per SEC Form D

Co-investorsCincyTech Sofinnova Ventures Ally Bridge Group

Angiexangiex.com in 𝕏Jul 2025SEC filingmedium confidence

Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells.

BiotechHealthtechMedical DevicesCambridge, US

Paul Jaminet(Executive Officer, Director)in

BoardErrik Anderson(Director)Jason Camm(Director)inJonathan Adams(Director)in Fabian Hansen(Director)in

Board seat Iain Dukes· per SEC Form D · $28.4M raise · filed Sep 2025

Co-investorsGreen Meadow Ventures K5 Global Mana Ventures

Audentes Therapeuticsastellasgenetherapies.com inAug 2015SEC filingmedium confidence

BiotechSan Francisco, US

Matthew Patterson(Executive Officer, Director)in

Board Steve Squinto(Director)in Kush Parmar(Director)in Jonathan Leff(Director)Thomas Woiwode(Director)

Board seat Jonathan Silverstein· per SEC Form D · filed Sep 2015

Co-investorsAsset Management Company RA Capital venBio Partners 5AM Ventures Deerfield Management Company Venrock

Averna Therapeuticsavernatx.com inApr 2024

Averna Therapeutics is a biotechnology company developing therapeutics.

BiotechDeep TechHealthtechMedical DevicesWatertown, US

Richard Morris(Chief Financial Officer)inThomas M. Barnes(CEO & Board Member)

BoardRoy Amariglio(Director)Nick Olsen(Director)inMichal Silverberg(Director)in

Board seat Stephen Squinto· per SEC Form D

Co-investorsDeep Insight Delos Capital Novartis Venture Fund ARC VENTURES Insight Partners

Belenos Biosciencesbelenosbio.comJul 2024

Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU.

BiotechHealthtechNew York, US

Donnie McGrath(CEO & Co-Founder)Megan Dow(COO & Co-Founder)Tania Dimitrova(CFO & Co-Founder)Glenn Rosen(Chief Translational Officer & Co-Founder)Donnie McGrath, M.D., M.P.H.(CEO & Co-Founder)inMegan Dow, Ph.D.(COO & Co-Founder)in

Board seat Carl L. Gordon· per SEC Form D

Cerapedicscerapedics.com in 𝕏Feb 2015 · $15M

Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.

BiotechHealthtechMedical DevicesWestminster, US

Andrew J. Tofe(Director)in Britt Pearson(Executive Officer)inJeff Marx(Executive Officer)in Glen Kashuba(Executive Officer, Director)inJerome Connor(Executive Officer)inAndrew Handwerker(Executive Officer)

Board seatChau Khuong Jonathan Silverstein· per SEC Form D

Co-investorsRevelation Partners NGN Capital

Chemomabchemomab.com inMar 2021

Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis.

BiotechHealthtechTel Aviv

Adi Mor(Executive Officer, Director)inAdi Mor George(Executive Officer, Director)Jill Quigley(Director)inSigal Fattal(Executive Officer)inMatthew Frankel(Executive Officer)in Arnon Aharon(Executive Officer)in

Board seat Stephen Squinto· per SEC Form D

Co-investorsAltium Capital SBI JI Innovation Advisory Ltd.

Convergent Therapeuticsconvergentrx.com in 𝕏May 2023 · $90M

Convergent Therapeutics develops radioantibody-based (PSMA-targeted) therapies for cancers, including metastatic castration-resistant prostate cancer (mCRPC).

BiotechHealthtechCambridge, US

Philip Kantoff(Chief Executive Officer, Co-Founder)inNeil Bander(Senior Scientific Advisor, Co-Founder)Alexander Brown(Executive Officer)in Andrew Davis(Chief Business and Strategy Officer)in Elizabeth L. Montgomery(Chief People Officer)inEric M. Sullivan(Chief Financial Officer)in

Board seat Tal Zaks· per SEC Form D

Co-investorsInvus RA Capital

Enlaza Therapeuticsenlazatx.com inAug 2025SEC filingmedium confidence

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.

BiotechDeep TechSan Diego, US

Sergio Duron(Co-Founder & Chief Executive Officer)in Sanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in

Board Marcos Milla(Director)in Jay Lichter(Director)in Tighe Reardon(Executive Officer)

Board seat Stephen Squinto· per SEC Form D · $15M raise · filed Sep 2025

Co-investorsFrazier Life Sciences Lightspeed Venture Partners Samsara BioCapital Avalon BioVentures Pappas Capital Pfizer Venture Investments +1 more

Gemini Therapeuticsgeminitherapeutics.comApr 2016 · $42.5M

Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.

BiotechCambridge, US

James McLaughlin(Executive Officer, Director)in

Board Jean George(Director)Jason Rhodes(Director)in Carl Gordon(Director)in

Board seat Carl L. Gordon· per SEC Form D

Co-investorsAltium Capital Lightstone Ventures Atlas Venture

Gennao Bio inMay 2021

Genetic medicines company developing targeted nucleic acid therapeutics via a gene monoclonal antibody platform.

BiotechPennington, US

Chris Duke(Mr. Duke is the Chief Operating Officer of the Issuer.)inDale Ludwig(Mr. Ludwig is the Chief Scientific Officer)in Anuj Goswami(Mr. Goswami is the General Counsel and Secretary)in Claudine Prowse(Ms. Prowse is the Chief Financial Officer)inGary Sender(Director)Julie Hambleton(Director)

Board seatChau Khuong· per SEC Form D

Inspire Medicalinspiresleep.com in 𝕏Oct 2016SEC filingmedium confidence

Inspire Medical Systems develops an FDA-approved implantable device that treats obstructive sleep apnea (OSA) by working with the patient's natural breathing, controlled via a small remote and intended for patients for whom CPAP is not effective.

Digital HealthHealthtechMedical DevicesGolden Valley, US

Tim Herbert(Founder)in

BoardMudit Jain(Director)Joyce Erony(Director)inDana Mead(Director)Casey Tansey(Director)

Board seatChau Khuong· per SEC Form D · $37.5M raise · filed Nov 2016

Co-investorsAmzak Health APERTURE Venture Partners US Venture Partners

Neurogastrxneurogastrx.com inJun 2021 · $60M

Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.

BiotechHealthtechWoburn, US

Cyril De Colle(Founder)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in

Board DAVID ALLISON(Director)in

Board seat Kevin Koch Klaus Veitinger· per SEC Form D

Co-investors5AM Ventures Samsara BioCapital venBio Partners Vivo Capital RTW Investments L.P.venBio Global Strategic +1 more

Noctrix Healthnoctrixhealth.comJan 2021 · $40M

Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.

Digital HealthMedical DevicesWellness & FitnessPleasanton, US

Shri Raghunathan(Founder)inShriram Raghunathan(Executive Officer, Director)

BoardAllan May(Director)Mudit Jain(Director)in Tracy Pappas(Director)in

Board seatChau Khuong· per SEC Form D

Co-investorsAngelini Ventures Blue Venture Funds Joyance Partners Treo Ventures, Llc Zühlke Ventures Bridge Bank +2 more

Pieris Pharmaceuticals inJun 2016SEC filingmedium confidence

BiotechBoston, US

Darlene Deptula-Hicks(Executive Officer)inStephen S. Yoder(Executive Officer, Director)in Darlene M. Deptula-Hicks(Acting Chief Financial Officer)in

BoardChristina Takke(Director)Steven Prelack(Director)

Board seatChau Khuong· per SEC Form D · $16.5M raise · filed Jun 2016

Co-investorsRidgeback Capital Biotechnology Value Fund Frazier Life Sciences

Promentis Pharmaceuticalspromentispharma.comDec 2019SEC filingmedium confidence

Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders.

BiotechHealthtechMental HealthMilwaukee, US

David Baker, PhD(Director)Daniel Lawton(Executive Officer, Director)Tom Beck(Executive Officer, Director)Chad Beyer(Executive Officer)Chad E Beyer, PhD(Executive Officer, Director)

Board seat Klaus Veitinger· per SEC Form D · $6M raise · filed Dec 2019

Co-investorsAisling Capital F-Prime Capital

Rhythm Pharmaceuticalsrhythmtx.com in 𝕏Aug 2015SEC filingmedium confidence

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)in Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in

Board Edward T. Mathers(Director)in Neil Exter(Director)in

Board seat Jonathan Silverstein· per SEC Form D · $40M raise · filed Dec 2015

Co-investorsForesite Capital HEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)Pfizer Venture Investments Wellington Management Third Rock Ventures

Sparrow Pharmasparrowpharma.com in 𝕏Jul 2025

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.

BiotechHealthtechMedical DevicesPortland, US

Robert Jacks(Executive Officer, Director)inDavid Aaron Katz(Executive Officer, Director)

Board Jonathan Root(Director)in Niall O'Donnell(Director)in Zach Scheiner(Director)in

Board seat Klaus Veitinger· per SEC Form D

Co-investorsRA Capital RiverVest Venture Partners US Venture Partners Forbion

Theseus Pharmaceuticalstheseusrx.comJun 2018

BiotechCambridge, US

William C. Shakespeare(Director)in

Board Iain Dukes(Executive Officer, Director)in Michael Rome(Director)in Carl Gordon(Director)in

Board seat Carl L. Gordon· per SEC Form D

Co-investorsForesite Capital Longitude Capital Nextech Invest NexTech Ventures Omega Funds Pontifax Venture Capital +2 more

Thrombolexthrombolex.com in 𝕏Feb 2026 · $50M

Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots.

BiotechHealthtechMedical DevicesKingston, US

Riyaz Bashir(Innovator / Creator of BASHIR Endovascular Catheters)John Cerminaro(Executive Officer)inMichael J. Cerminaro(Executive Officer, Director)inMarvin Woodall(Executive Officer, Director)Brian G. Firth(Executive Officer, Director)Todd Richmond(Director)

Board seat David Bonita· per SEC Form D

Co-investorsDelaware Crossing Investor Group

Treeline Biosciencestreeline.bioAug 2025

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.

AI & Machine LearningBiotechHealthtechMedical DevicesWatertown, US

Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)inJosh Bilenker Jeff Engelman(Founder)

Board Kristina Burow(Director)inAli Satvat(Director)

Board seat David Bonita· per SEC Form D

Co-investorsAisling Capital ARCH Venture Partners GV (Google Ventures)ARC VENTURES Casdin Capital Exor +3 more

Tricidatricida.comSeries A · Jul 2016 · $42M

BiotechSouth San Francisco, US

Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)

BoardSandra Coufal(Director)Robert Alpern(Director)

Board seat Klaus Veitinger David Bonita· per SEC Form D

Co-investorsAvoro Capital Advisors Longitude Capital Wellington Management Frazier Life Sciences Hercules Capital, Inc.

Vanqua Biovanquabio.com in 𝕏Series B · Aug 2021 · $85M

Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.

BiotechDeep TechHealthtechLongevityChicago, US

Rand Sutherland(Director)in Jim Sullivan(CEO)in Kevin Hunt(CSO)in

BoardBernard Davitian(Director)Uya Chuluunbaatar(Director)

Board seat Jonathan Silverstein Stephen Squinto Mona Ashiya· per SEC Form D

Co-investorsAvoro Capital Advisors OUP (Osage University Partners)Pontifax Venture Capital Casdin Capital Omega Funds

Viewrayviewray.com in 𝕏Dec 2014SEC filingmedium confidence

ViewRay develops MRIdian A3i, an MRI-guided radiation therapy system that uses diagnostic-quality MRI imaging for real-time tissue tracking and automated beam control during cancer treatment.

HardwareHealthtechMedical DevicesOakwood Village, US

James F. Dempsey(Executive Officer, Director)inDavid Chandler(Mr. Chandler is the Chief Financial Officer of the Issuer.)Chris A. Raanes(Executive Officer, Director)Michael Brandt(Executive Officer)D. David Chandler(Executive Officer)Gregory M. Ayers(President and Chief Executive Officer of the Issuer.)

Board seat David Bonita· per SEC Form D · filed Aug 2015

Co-investorsAisling Capital F-Prime Capital Xeraya Capital

4646.capitalJan 2023 · $46M

46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.

Fintech

Tim Clark(Managing Director)

Co-investorsHurricane Ventures Andreessen Horowitz Ascenta Capital Avaana Capital BoxGroup Claypond Capital +7 more

Adcendo ApSadcendo.com

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsVida Ventures HealthCap Jeito Capital Novo Holdings Pontifax Venture Capital RA Capital +3 more

Adimabadimab.com in

Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system.

AI & Machine LearningBiotechDeep TechVermont, US

Co-investorsGrandBanks Capital LaunchCapital Lux Capital Mithril Capital Management Premji Invest SV Health Investors +1 more

Advancedenzymesadvancedenzymes.com

Advanced Enzymes is a company in the enzyme/biotech industry; the page shown is an investor relations section with quarterly financial results, shareholding patterns, and corporate governance reports.

BiotechFoodTechNew Materials

Aerin Medicalaerinmedical.com in 𝕏Feb 2025

Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.

HealthtechMedical DevicesMountain View, US

Matt Brokaw(CEO & President)inDerrick Sung(Executive Officer)inMatthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)inAndre Cheng(Executive Officer)inFred Dinger(Executive Officer, Director)in

Co-investorsLaunchCapital Questa Capital Targeted Technology Funds Ally Bridge Group Horizon

Aimsindiaaimsindia.com in 𝕏

Asian Institute of Medical Sciences is a hospital in India providing healthcare services with accreditation from NABH, NABL, and AACI.

Digital HealthHealthtechMedical DevicesFaridabad, IN

AirNexis Therapeuticsairnexis.com inJan 2026

Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.

BiotechPalo Alto, US

James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)in

BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)Jill Carroll(Director)in

Co-investorsFrazier Life Sciences Longitude Capital SR One Capital Management

Airstripairstrip.com in 𝕏Oct 2019 · $50M

AirStrip develops clinical decision support and patient monitoring software, including data-driven and AI predictive analytics tools, for hospitals, health systems, and clinicians.

AI & Machine LearningDigital HealthHealthtechMedical DevicesSaaSSan Antonio, US

Alan Portela(Executive Officer, Director)inDr. Naseem(Chief Executive Officer)Lauren Schiegg(Chief Operating Officer)inHari Radhakrishnan(Chief Medical Officer)in Sken Huang(Chief Financial Officer)inRory(Chief Commercial Officer)

Ak Medicalak-medical.net

AK Medical is a company providing investor and corporate information, headquartered in Beijing with a principal place of business in Hong Kong.

Advanced ManufacturingHardwareHealthtechMedical DevicesBeijing, CN

Co-investorsDecheng Capital

Alpine Immune Sciencesalpineimmunesciences.com inSep 2021 · $91M

BiotechSeattle, US

Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)

Co-investorsDecheng Capital Frazier Life Sciences Biotechnology Value Fund

Alterome Therapeutics, Inc.alterome.com inSeries A · Dec 2021 · $64M

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.

AI & Machine LearningBiotechDeep TechSan Diego, US

Eric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)Richard Heyman(Founder)

Board Thilo Schroeder(Director)in Carl Gordon(Director)in Arjun Goyal(Director)in

Co-investorsCanaan Partners Nextech Invest Vida Ventures Digitalis Ventures NVIDIA

Altis Labsaltislabs.com in 𝕏

Altis Labs provides a web-based platform that applies AI models to medical imaging data to generate reproducible predictions and quantifications for clinical trials.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesToronto, CA

Felix Baldauf-Lenschen(Founder & CEO)inJohn(CTO)

Co-investorsCreative Destruction Lab (CDL)Debiopharm Innovation Fund Fusion Benchstrength Partners

Amolyt Pharmaamolytpharma.comJan 2023 · $138M

Developing therapeutic peptides targeting rare endocrine diseases (past investment).

Co-investorsAndera Partners ATEM Capital Fund CTI Life Sciences Fund L.P.EQT Life Sciences Kurma Partners Octalfa +4 more

Anchordxanchordx.com

AnchorDx develops, manufactures, and sells cancer early-screening and diagnostic products based on ctDNA methylation high-throughput sequencing, along with related testing services covering over 70% of high-incidence cancers such as lung, breast, digestive, and urinary cancers.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesGuangzhou, CN

范建兵(Founder)

Co-investorsMarathon Venture Partners 6 Dimensions Capital

Angitia Bioangitiabio.com

Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.

Biotech

Co-investorsAscenta Capital Frazier Life Sciences RA Capital Wellington Management Frazier

Arcatronarcatron.com 𝕏

Arcatron designs and sells mobility and assistive products under the Frido brand, including electric and manual wheelchairs, mobility scooters, transfer lifts, walking aids, shower and hygiene aids, and bath mats.

ConsumerE-commerceMedical Devices

Dewaj Baruah(Founder)in

Co-investorsJetty Ventures

Architect Therapeuticsarchitecttherapeutics.com

Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets.

BiotechDeep TechSan Diego, US

Jin-Quan Yu(Founder)inJin-Quan Yu, Ph.D.(Scientific Founder)Ben Cravatt Ph.D.(Scientific Founder)Rich Heyman, Ph.D.(Scientific Founder)Angie You, Ph.D.(Chief Executive Officer)

Co-investorsFrazier Life Sciences Viking Global

Arriventarrivent.com inDec 2022

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)in Brent Rice(Chief Commercial Officer)in

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCatalio Capital Management, LP Foresite Capital General Catalyst HBM Healthcare Investments HBM Partners HongShan Capital Group +4 more

ARS Pharmaceuticalsars-pharma.com in 𝕏

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)

BoardJonathan Leff(Director)

Co-investorsNextech Invest RA Capital SR One Capital Management Sofinnova Ventures

Athenexathenex.com inMay 2019 · $100M

BiotechBuffalo, US

Flint Besecker(Executive Officer, Director)inLi Shen(Executive Officer)inSimon Pedder(Executive Officer)inJohnson Lau(Executive Officer, Director)inWilliam Zuo(Executive Officer)Rudolf Kwan(Executive Officer)

Co-investorsAvoro Capital Advisors Salica Investments

Augmedixaugmedix.com in 𝕏Dec 2016 · $23MAcquired

Augmedix builds AI-driven documentation technology for clinicians, aiming to reduce time spent on technology so providers can focus on patient care.

AI & Machine LearningDigital HealthHealthtechSan Francisco, US

Ian Shakil(Executive Officer, Director)in Pelu Tran(Cofounder)in Emmanuel Krakaris(Executive Officer, Director)inPaul Ginocchio(Executive Officer)inSandra Breber(Executive Officer)inJoseph Marks(Director)

Co-investorsDCM Ventures Evolution VC Partners Great Oaks Venture Capital LifeSci Venture Partners OVO Fund Sand Hill Angels +3 more

Avedro, Inc.avedro.com in 𝕏Jan 2019 · $32Macquired by Glaukos

BiotechHealthtechMedical DevicesWaltham, US

David F. Muller(Executive Officer, Director)in Brian J. Roberts(Executive Officer)in Rhonda J. Bracey(Executive Officer)in

BoardJason Hong(Director)Jeff Dykan(Director)in Anthony Natale(Director)in

Co-investorsAPERTURE Venture Partners LAV Lilly Asia Ventures SCP Vitalife Partners Third Point Ventures Abingworth +4 more

Avenzoavenzotx.com inNov 2024 · $60M

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

BiotechSan Diego, US

Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in

BoardCarl Gordon(Director)

Co-investorsDelos Capital Foresite Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)Quan Capital +6 more

Aviceda Therapeuticsavicedarx.com in 𝕏

Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Michael Tolentino(Executive Officer, Director)in Mohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inDerek Kunimoto(Executive Officer)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in

Co-investorsJeito Capital Longitude Capital Catalio Capital Management, LP Avoro Capital Advisors Digitalis Ventures Omega Funds

Avitideavitide.comJun 2017acquired by Repligen

Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.

BiotechHardwareMedical DevicesLebanon, US

Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)

Co-investorsSV Health Investors Borealis Ventures Mithril Capital Management Neomed Management Polaris Partners Sands Capital Ventures +1 more

Azuraazura.xyzOct 2017 · $20M

Azura is an onchain trading platform that lets users trade any onchain asset using USD without bridging, gas, or wallet management, at zero fees.

Crypto & Web3Fintech

Co-investorsAlliance DAO (ex DeFi Alliance)De Fi Alliance Holdings Initialized Capital Thanefield Capital Transpose Platform Management Raj Gokal +2 more

Azuraophthalmicsazuraophthalmics.com in 𝕏

Azura Ophthalmics develops a new therapeutic class of ophthalmic keratolytics aimed at treating lid margin and ocular surface diseases and other underserved ophthalmic conditions.

BiotechHealthtechMedical Devices

Luba(Director of Pre-Clinical Development)

Beijing Star Sports Medicinestar-sportsmed.com in 𝕏

Manufactures surgical instrument sets and tools for orthopedic procedures such as hip arthroscopy, including curettes, probes, rasps, tissue elevators, and suture manipulation devices.

HardwareHealthtechMedical DevicesSports Tech

Bhtherapeuticsbhtherapeutics.com

BH Therapeutics is a drug development company that uses structure-based rational drug design to identify structural limitations in existing therapies and design novel chemical scaffolds to address them.

Biotech

J. Jean Cui, Ph.D.(Scientific Founder, President and CEO)Y. Peter Li, Ph.D., MBA(Cofounder and Executive Chairman)

Co-investorsVivo Capital

Binx Healthmybinxhealth.com inMay 2021

binx health develops FDA-cleared, CLIA-waived point-of-care diagnostic testing for chlamydia and gonorrhea in male and female patients, delivering central-lab-quality results in about thirty minutes so patients can test, get diagnosed, and receive treatment in one visit.

BiotechDigital HealthHealthtechMedical DevicesTrowbridge

Anna Dixon(Executive Officer)inMarc Jones(Executive Officer)inJeffrey R. Luber(Executive Officer, Director)in

BoardAndrew Goldman(Director)Martin Munchbach(Director)Jihua Wang(Director)

Co-investorsAsabys Partners

Biobeatbio-beat.com in 𝕏

Biobeat develops a cuff-less, ambulatory blood pressure monitoring system built around a proprietary PPG sensor and a platform for tracking vital signs, aimed at helping physicians diagnose and manage hypertension.

Digital HealthHealthtechMedical Devices

Arik B.(Founder)inArik Ben Ishay(Founder & CEO)Johanan May(Founder, SVP & CTO)in Israel Sarussi(Founder, SVP R&D)in Michael Gioffredi(CCO)in

BoardRaymond W. Cohen(Chairman of the Board)

Co-investorsAlly Bridge Group Raptor Group

Biohaven Pharmaceuticalsbiohavenpharma.com in 𝕏Sep 2020 · $60M

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.

BiotechHealthtech

Vlad Coric(Chairman & Chief Executive Officer)in

Co-investorsAisling Capital APERTURE Venture Partners Connecticut Innovations OUP (Osage University Partners)HBM Healthcare Investments

Bonovo Orthopedicsbonovo-ortho.com

Leading provider of orthopedic products to the Chinese healthcare market.

Co-investorsLegend Capital

Braveheartbraveheart.bio in

Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.

BiotechDigital HealthHealthtechMedical Devices

Travis Murdoch, M.D.(Chief Executive Officer and Board Director)in

Co-investorsAndreessen Horowitz Frazier Life Sciences Forbion

Candid Therapeuticscandidrx.com inAug 2024

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsForesite Capital LifeSci Venture Partners Samsara BioCapital TCG Crossover Third Rock Ventures venBio Partners +2 more

Carrot Fertilityget-carrot.com in 𝕏Series C · Aug 2021 · $75M

Carrot is a global fertility and family-building platform that provides access to fertility care, maternity support, and family-building guidance for individuals and families.

FemTechHealthtechHR TechSan Francisco, US

Asima Ahmad(CMO)in Tammy Sun(Founder)inDavid Utley(Executive Officer, Director)Dr. Asima Ahmad(Founder)Arun VenkatesanMaxwell Radomsky

Co-investors515 Ventures All Turtles Aurum Backstage Capital Core Venture Capital CRV (Charles River Ventures)+18 more

Cellipont Bioservicescellipont.com in 𝕏

Cellipont Bioservices is a contract development and manufacturing organization (CDMO) that provides GMP manufacturing and development services for advanced cell therapies.

Advanced ManufacturingBiotechHealthtechThe Woodlands, US

Cerecor Inc.avalotx.com in

Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.

BiotechMedical DevicesBaltimore, US

Blake M. Paterson(Executive Officer, Director)Mariam Morris(Executive Officer)in Ronald Marcus(Executive Officer)inUli Hacksell(Executive Officer, Director)John Kaiser(Executive Officer)inJames Vornov(Executive Officer)in

Co-investorsNew Enterprise Associates (NEA)

Charmwithcharm.appSep 2025 · $80M

Charm is a payments and savings app that enables users to send money across different platforms (Venmo, Cash App, Zelle) through a unified interface, with funds earning interest when held in the app.

ConsumerCrypto & Web3FintechSocialNew York City, US

Gray Newfield(Founder)in Noah Newfield(Founder)inChristian Rocha(Founder)Toby Padilla(Founder)

Co-investorsPioneer Y Combinator 468 Capital Cavalry Ventures F-Prime Capital Firestreak Ventures +7 more

Charmcharm.land 𝕏Sep 2025 · $80M

Charm builds open-source tools and libraries for creating user interfaces and applications in the terminal, including command-line interface frameworks, markdown readers, and components for developers.

Developer Tools

Co-investorsBetaworks Cavalry Ventures Gradient Ventures Lowercarbon Capital Motive Force NAP +5 more

Charmcharm.fi 𝕏Sep 2025 · $80M

Charm.fi is a decentralized finance platform offering automated liquidity management vaults on Ethereum, letting users browse or create vaults for any token and build LP strategies to manage liquidity and earn yields.

Crypto & Web3Fintech

Co-investorsCoinbase Ventures Cavalry Ventures F-Prime Capital Fuel Capital Gradient Ventures Khosla Ventures +2 more

CHARM Therapeuticscharmtx.com in

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.

AI & Machine LearningBiotechHealthtechLondon

Lakshyaditya Singh Aithani(Executive Officer, Director)David Baker(Founder)Laksh Aithani(Founder)

Board Rishi Gupta(Director)in Nihal Sinha(Director)in Muzammil Mansuri(Director)in

Co-investorsF-Prime Capital New Enterprise Associates (NEA)SR One Capital Management Axial VC Khosla Ventures NVentures

Civitas Therapeuticscivitastherapeutics.comAug 2014

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)in MARK IWICKI(Executive Officer, Director)in MARTIN FREED(Executive Officer)in

Board ROB HOPFNER(Director)in

Co-investorsCanaan Partners Longitude Capital Sofinnova Ventures Bay City Capital Fountain Healthcare Partners RA Capital

Cleave Biosciencescleavetherapeutics.com

BiotechBurlingame, US

Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)

Board Alfred Scheidegger(Director)in Peter Thompson(Director)in Carol Gallagher(Director)in

Co-investorsAstellas Venture Management LLC New Enterprise Associates (NEA)Nextech Invest OUP (Osage University Partners)5AM Ventures Clarus Ventures +1 more

Convergentconvergent.org inMay 2023 · $90M

Convergent provides an AI simulation platform for enterprise training and skill development.

AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB

Co-investorsTechstars Andreessen Horowitz RA Capital

Corvus Pharmaceuticalscorvuspharma.com in

Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.

BiotechHealthtechBurlingame, US

Richard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in

BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Co-Founder)inTerry G. Gould(Director)

Co-investorsAvoro Capital Advisors Foresite Capital

Creaternacreaterna.com

Lang Lai Technology (朗来科技) is a clinical-stage drug discovery company that runs an end-to-end new-drug R&D process spanning proof of concept, candidate compound screening, preclinical druggability development, and clinical research, pursuing both pipeline development and platform building.

BiotechHealthtechWuhan, CN

Co-investorsVivo Capital Lilly Asia Ventures

Curevo Vaccinecurevovaccine.com inMar 2025 · $110M

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.

BiotechHealthtech

George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in

Co-investorsAdjuvant Capital RA Capital Sanofi Ventures HBM Healthcare Investments Janus Henderson Investors Medicxi

Cyrus Biotechnologycyrusbio.com in 𝕏

Cyrus operates a protein engineering platform that combines AI and Rosetta computational design methods with a biochemistry lab performing large-scale deep mutagenesis scanning, protein stabilization, immunogenicity reduction, and affinity/specificity tuning.

AI & Machine LearningBiotechDeep TechSeattle, US

Yifan Song(CSO)inDavid Baker(Co-founder)Javier Castellanos(Executive Officer, Director)inMark(President & EVP, Business Development)

Board Lucas Nivon(CEO)in

Co-investorsAlumni Ventures Anzu Partners Argonautic Ventures iSelect Fund SPRINGROCK VENTURES Strawberry Creek Ventures +4 more

Cyrus Securitycyrus.app in 𝕏Acquired

Cyrus provides a mobile app for personal cybersecurity and financial protection, offering account monitoring, dark web scanning, credit monitoring across three bureaus, VPN services, and fraud support for consumers.

ConsumerCybersecurityDigital Health

Co-investorsRainfall Ventures Resolute Ventures SPRINGROCK VENTURES The Fintech Fund Trinity Ventures

Dami & Xiaomidmhxm.com

大米和小米 (DMHXM) operates a network of over 80 directly-run centers across more than 30 Chinese cities providing in-person early intervention and rehabilitation therapy for children with autism and developmental disorders, staffed by BCBA/BCaBA-certified therapists and experienced supervisors.

Digital HealthHealthtechWellness & FitnessShenzhen, CN

Co-investorsYuanBio Venture Capital

Delfi Diagnosticsdelfidiagnostics.com in

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

Victor Velculescu(Founder)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)in Susan Tousi(Chief Executive Officer)in

Co-investorsAV8 Ventures Foresite Capital Illumina Ventures Initiate Venture Partners Menlo Ventures Merck Global Health Innovation Fund +7 more

Dihdih.com in

DIH is a healthcare technology company that develops rehabilitation and robotic therapy devices and software (including the Hocoma product line) for the medical and healthcare industry.

Digital HealthHardwareHealthtechMedical DevicesRoboticsZurich, CH

Jason(CEO and Chairman of the Board)

Dimension Therapeutics inApr 2015acquired by Ultragenyx Pharmaceutical · Oct 2017 · $152.3M

Dimension Therapeutics was a Cambridge, Massachusetts biopharmaceutical company developing AAV-based gene therapies for rare liver-associated metabolic diseases like hemophilia, OTC deficiency, and glycogen storage disease.

Cambridge, US

Annalisa Jenkins(Executive Officer, Director)

BoardBenjamin Auspitz(Director)Donald J. Hayden(Director)Allan Fox(Director)

Co-investorsF-Prime Capital New Leaf Venture Partners

EC Healthcareechealthcare.com in

EC Healthcare provides medical aesthetic and healthcare services, including sales of medical aesthetic products, to consumers.

ConsumerDigital HealthHealthtechWellness & FitnessHong Kong, HK

Eilean Therapeuticseileanther.com

Eilean Therapeutics is a small molecule oncology drug discovery company developing pan-variant therapies that target resistance mechanisms in hematologic malignancies.

BiotechHealthtech

Iain Dukes(CEO)inJohn Byrd(Interim Chief Medical Officer)Nikolay Savchuk(COO)Amy Burd(CSO)Brian Ledwith(Chief Development Officer)Fraser Pickersgill(Head CMC)

Electra Therapeuticselectra-therapeutics.com inSeries B · Oct 2025 · $84M

Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in

BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)

Co-investorsHBM Healthcare Investments HBM Partners RA Capital Westlake Village BioPartners Kleiner Perkins NVIDIA

Epigenic Therapeuticsepigenictx.com in

Epigenic Therapeutics develops gene regulation-based biotherapeutics using its EPIREG platform, which applies AI algorithms to design CRISPR-Cas components that regulate target gene expression without altering the DNA sequence.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Chloe You(Chief Medical Officer)inKelly Shi(Chief Financial Officer)

Co-investorsQiming Venture Partners Trinity Innovation Bioventure Singapore

Evox Therapeuticsevoxtherapeutics.com in 𝕏

Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.

BiotechDeep Tech

Co-investorsGV (Google Ventures)Oxford Science Enterprises Panacea Venture Cowen Healthcare Investments REDMILE

Evozyneevozyne.com inSeries B · Sep 2023 · $81M

Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases.

AI & Machine LearningBiotechDeep TechHealthtechChicago, US

Aris Theologis(Executive Officer, Director)inDarien Parhad(Executive Officer)Patrick J. Morris(Executive Officer, Director)Marc Yoskowitz(CEO)inRama Ranganathan(Founder)Andrew Ferguson(Founder)

Co-investorsParagon Biosciences LLC In-Q-Tel Valor Equity Partners Fidelity Investments NVentures NVIDIA

Fore Biotherapeuticsfore.bio in 𝕏

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsHBM Healthcare Investments HBM Partners LG Technology Ventures Novartis Venture Fund Pontifax Venture Capital SR One Capital Management +4 more

ForteBiofortebio.comSep 2008 · $25Macquired by Pall

Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.

Co-investorsLatterell Venture Partners MPM BioImpact The Vertical Group Versant Ventures

Fridomyfrido.com in 𝕏Feb 2024

Frido sells the Arch Comfort Slides, unisex footwear with a contoured EVA footbed offering built-in arch support and a slip-resistant sole.

ConsumerDirect to ConsumerE-commerceWellness & FitnessPune, IN

Ganesh Sonawane(Founder)in

Fusion Pharmaceuticalsfusionpharma.com in 𝕏Apr 2019 · $105M

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

John Valliant(Founder)in

Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCap Lumira Ventures Pivotal Life Sciences Seroba Life Sciences Venture Ontario +6 more

Fusmobilefusmobile.com in 𝕏

FUS Mobile develops the Neurolyser XR, a non-invasive medical device that uses high intensity focused ultrasound (HIFU) with fluoroscopic guidance to thermally ablate the lumbar medial branch nerve for treating chronic facet-mediated low back pain.

Deep TechDigital HealthHardwareHealthtechMedical Devices

Co-investorsAtlanta Technology Angels

Galecto Biotechgalecto.com

Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis.

BiotechMedical Devices

Jennifer Jarrett(Chief Executive Officer & Board Director)in Sherwin Sattarzadeh(Chief Operating Officer)inBecker Hewes(Chief Medical Officer)Garrett Winslow(General Counsel)in Jim Baker(Chief Corporate Affairs Officer)inBrian Burkavage(Senior Vice President, Finance)in

Co-investorsEIR Ventures Hadean Ventures M Ventures SEED Capital Denmark Seventure Partners Sunstone Capital +3 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

BELLUS HealthClementia PharmaceuticalsCurevo, Inc.FORE US Bio Igenica Biotherapeutics Ikena Oncology, Inc.Prevail Therapeutics Restora Medical SpringWorks Therapeutics Symbiomix TherapeuticsADARxAduro BiotechAige010Aragon Pharmaceuticals AttenuaAvalo TherapeuticsAzura OpthalmicsBailiBiokinBionovapharmaBlossomHill TherapeuticsCreditpharmaDlabsciEddingpharmEthrisEurolifehealthcareForSight VISION6 IncFortebiorxFuturx

Browse all 338 investments with full details →

▶138 more tracked companies

GaushGelesis GenewizGennaoGenocuryGood Doctor Cloud HealthHarpoon Therapeutics Harvestiro Helicore BiopharmaHysyylIambic IkenaoncologyImmune PathInnovate BiopharmaceuticalsInnvolutionInnvolution Healthcare Private LimitedIntellia Inventisbio Iswarya Fertility Janux Therapeutics Jinxin Fuxing EldercareJxfxkyKapiva Kartosthera Koya Medical Kumquat Biosciences Laekna TherapeuticsLattice MedTech Private LimitedLaxmi DentalLaxmidentalleal Leal Therapeutics Lexeotx Lifecell Logicbio Lomondther Loxo Loxo Oncology Lupeng Pharmaceutical Lycia Therapeutics Magenta Medical Marksans Pharma MBX Biosciences MDxHealth Medpharm MemeBox Mendra MID LabsMinghuipharmaMinvervaXMirador Mirador TherapeuticsMobileodtMondegobio Myriad Genetics NanotronicsNerre TherapeuticsNeurelis NewmedNorchem PharmaNucleix Nucleusrad Odyssey Therapeutics Path Ai Pathalys Pee Safe Pic Therapeutics Pinnacle Medicines Pionyr Immunotherapeutics PMV Pharma Postmates Practice Fusion Principia BiopharmaProlynxProlynxinc Propeller ProVerumProviva TherapeuticsPulnovo MedicalRadiuspharm Rampart Bioscience RAPT Therapeutics RayThera ReCode TherapeuticsReliabiotechRenasant BioRepare TherapeuticsReparerxReViral Seroba Life Sciences Sidewinder Therapeutics Sikka Sikkasoft Silverback Therapeutics Singulex Sitala SiteOne TherapeuticsSneuroSpectronrx Stairmed Star Therapeutics Starling Oncology Stratus Therapeutics Suraksha Diagnostic Synthorx TandemaiTendfoTerremotobio The Oncology Institute TheseusThird Harmonic BioTigerConnect Topaz Tx TP TherapeuticsTriSalus Life SciencesTrisaluslifesci Triveni Trunativ Turnstone BiologicsTytoTyto Care UnilifeUpper BiotechUrotronic Velosbio Velsera Verdiva BioVerrica PharmaceuticalsVivacta BioVvardis Windward BioYarrowYarrowbioscience ZaiZentera TherapeuticsZenteratxZion Pharma Zyloxtb

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 63

51 IPOs · 12 acquisitions · showing 56

Portfolio news

latest coverage across their companies

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

Caris Life Sciences · finance.yahoo.com · Sep 8, 2026

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY | Invivyd

Invivyd · investors.invivyd.com · Sep 1, 2026

Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science – GeekWire

Adaptive Biotechnologies · geekwire.com · Aug 18, 2026

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace · finance.yahoo.com · Aug 11, 2026

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates - ORIC Pharmaceuticals

ORIC Pharmaceuticals · oricpharma.com · Aug 3, 2026

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

SI-BONE · finance.yahoo.com · Aug 3, 2026

Investor Overview - Verrica Pharmaceuticals

Verrica · verrica.com · Jul 30, 2026

Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science - BioSpace

Insilico Medicine · biospace.com · Jul 30, 2026

Fund performance · per public LP disclosures · 10

as of Sep 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
OrbiMed Private Investments IX, LPLPs: California State Teachers' Retirement System, New Mexico Educational Retirement Board, Kern County Employees' Retirement Association	2022	—	29.3%	1.16x	0.21x
OrbiMed Royalty & Credit Opportunities IVLPs: California State Teachers' Retirement System, Sacramento County Employees' Retirement System, Kern County Employees' Retirement Association	2022	—	14.1%	1.28x	0.25x
OrbiMed Private Investments VIII, L.P.LPs: California State Teachers' Retirement System, New Mexico Educational Retirement Board	2020	—	6.9%	1.19x	0.30x
OrbiMed Royalty & Credit Opportunities III, LPLPs: California State Teachers' Retirement System, Sacramento County Employees' Retirement System	2019	—	15.1%	1.20x	0.95x
OrbiMed Private Investments VILPs: Oregon Public Employees Retirement System	2015	—	13.0%	1.64x	1.18x
OrbiMed Private Investments VLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System	2013	—	38.2%	2.35x	2.14x
OrbiMed Private Investments IVLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System, The Regents of the University of California +1 more	2009	—	31.8%	2.73x	2.72x
Orbimed Private lnvesuncnts IV, L PLPs: The Regents of the University of California	2009	—	36.2%	2.67x	0.45x
Orbimed Private Investments III, LPLPs: The Regents of the University of California	2006	—	18.1%	2.34x	1.48x
Orbimed Private lnvesunents Ill, LPLPs: The Regents of the University of California	2006	—	18.4%	2.32x	—

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

IPO stake values · per SEC filings · 17

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Prelude Therapeutics	28.8%	$60.00	Jan 2021	$935.7M
Passage Bio	14.2%	$18.00	Feb 2020	$112.7M
NextCure	10.1%	$36.75	Nov 2019	$99.6M
Adagio Therapeutics	4.6%	$17.00	Aug 2021	$84.7M
Invivyd	4.6%	$17.00	Aug 2021	$84.7M
Upstream Bio	9.5%	$17.00	Oct 2024	$82.8M
ORIC Pharmaceuticals	8.2%	$23.00	Nov 2020	$67.2M
Adicet Bio	15.8%	$15.00	Jan 2018	$64.5M
NeuroPace	16.4%	$17.00	Apr 2021	$64.2M
Calcimedica	17.9%	$16.00	Sep 2020	$57.6M
Sionna Therapeutics	7.4%	$18.00	Feb 2025	$56.8M
Damora Therapeutics	13.7%	$15.00	Oct 2020	$50.4M
Intellia Therapeutics	6.9%	$18.00	May 2016	$43.4M
Enliven Therapeutics	9.6%	$16.00	Mar 2020	$25.5M
Imara	9.6%	$16.00	Mar 2020	$25.5M
Verrica	5.1%	$15.00	Jun 2018	$19.2M
Scribe Therapeutics	2.0%	$15.00	Jul 2026	$5.2M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has OrbiMed made?: OrbiMed has 338 tracked investments, 63 of which have exited, including 38 dated in the last 24 months.
What stage does OrbiMed invest at?: OrbiMed invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is OrbiMed's typical check size?: OrbiMed typically writes checks of $1M – $75M.
What sectors does OrbiMed focus on?: OrbiMed focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is OrbiMed located?: OrbiMed is headquartered in New York, US.
Does OrbiMed lead rounds?: Yes, OrbiMed leads investment rounds.
Who does OrbiMed co-invest with?: OrbiMed most often shares deals with Foresite Capital, RA Capital, Frazier Life Sciences, among 274 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Geoffrey C. Hsu, CFA, General Partner, OrbiMed Advisors LLC

Biotechnology Innovation Organization · Geoffrey C. Hsu

Co-investors · 87

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Foresite Capital

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.

Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.

Both backed · 18

NextCure Passage Bio 46 ADARx Pharmaceuticals Arrivent Avedro, Inc.Avenzo BlossomHill Therapeutics Createrna Gracellbio Harpoon Therapeutics Insilico Medicine Inventisbio Lupeng Pharmaceutical Nucleix Perfuse Therapeutics Quantxbio TP Therapeutics

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 17

Enliven Therapeutics Imara Mirna Therapeutics NeuroPace ORIC Pharmaceuticals Synlogic Avenzo Brenig Cerecor Inc.Charm CHARM Therapeutics Cleave Biosciences Loxo Oncology Magenta Medical MBX Biosciences Pionyr Immunotherapeutics Rhythm Pharmaceuticals

$200K – $40M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

Both backed · 15

BioAge Labs Biomx Mirna Therapeutics NextCure Synlogic Aerpio Therapeutics Arrivent ARS Pharmaceuticals Avenzo Civitas Therapeutics Oncusp Therapeutics Pionyr Immunotherapeutics Principia Biopharma Star Therapeutics Velosbio

$100K – $15M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 14

Compass Therapeutics Insmed Adela Carrot Fertility Charm CHARM Therapeutics Dimension Therapeutics Insilico Medicine Oncusp Therapeutics Promentis Pharmaceuticals Symbiomix Therapeutics Tandemai Turnstone Biologics Viewray

$3M – $10M

SR One Capital Management

SR One Capital Management is a life sciences venture capital firm that takes a 'back-and-build' approach, providing entrepreneurs with human, intellectual, and financial resources. It emerged from the legacy SR One team formerly part of GSK.

Both backed · 12

Alumis 46 ADARx Pharmaceuticals AirNexis Therapeutics ARS Pharmaceuticals Avenzo CHARM Therapeutics Fore Biotherapeutics Kartosthera Odyssey Therapeutics Principia Biopharma Windward Bio

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.

Both backed · 12

Arvinas Holding Co. LLC Crinetics Pharmaceuticals Disc Medicine Enliven Therapeutics Q32 Bio Audentes Therapeutics Cleave Biosciences Igenica Biotherapeutics Mendra Neurogastrx Renasant BioProlynx

$100K – $4M

Samsara BioCapital

Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.

Both backed · 12

Alumis Upstream Bio Alpheus Medical Candid Therapeutics Delfi Diagnostics Enlaza Therapeutics Janux Therapeutics Neurogastrx Ottimo Pharma Pathalys Principia Biopharma SpringWorks Therapeutics

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 11

Disc Medicine Intellia Therapeutics Q32 Bio Sionna Therapeutics Synlogic Gemini Therapeutics Ikena Oncology, Inc.Ikenaoncology Renasant Bio TriveniThird Harmonic Bio

$500K – $1M

OUP (Osage University Partners)

OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.

Both backed · 10

Mirna Therapeutics Q32 Bio Biohaven Pharmaceuticals Cleave Biosciences Delfi Diagnostics Pionyr Immunotherapeutics PMV Pharma ReCode Therapeutics Synthorx Vanqua Bio

$1M – $20M

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 10

CytomX Therapeutics Enliven Therapeutics Imara Mirna Therapeutics NextCure Synlogic Enlaza Therapeutics ReCode Therapeutics Rhythm Pharmaceuticals SpringWorks Therapeutics

$5M – $20M

▶75 more co-investors

Aisling Capital Vivo Capital Nextech Invest Sanofi Ventures Avoro Capital Advisors HBM Partners venBio Partners Andreessen Horowitz GV (Google Ventures)Versant Ventures Omega Funds Canaan Partners US Venture Partners Forbion Deerfield Management Company New Leaf Venture Partners RTW Investments L.P.Khosla Ventures Kleiner Perkins Third Rock Ventures Abingworth Pivotal Life Sciences SV Health Investors Andera Partners Advent Life Sciences Founders Fund Lightspeed Venture Partners The Column Group Frazier Healthcare Partners Vida Ventures Westlake Village BioPartners JMI Equity Borealis Ventures Sequoia Capital General Catalyst Menlo Ventures Tiger Global Management Trinity Ventures Venrock Polaris Partners Pear VC Pitango Sofinnova Partners MPM BioImpact Hatteras Venture Partners Ysios Capital 6 Dimensions Capital Longwood Fund Bessemer Venture Partners CRV (Charles River Ventures)General Atlantic EQT Life Sciences Dimension Capital RiverVest Venture Partners DCVC (Data Collective)Meritech Capital Partners Domain Associates Flagship Pioneering 1955 Capital DFJ Seroba Life Sciences Amplitude Venture Capital Action Potential Venture Capital Ltd.ACORN BIOVENTURES CincyTech De Novo Ventures Signet Healthcare Partners Welsh, Carson, Anderson & Stowe Zetta Venture Partners Wildcat Venture Partners M12 (Microsoft's Venture Fund)BDC Venture Capital Tencent Holdings Cofounders Capital +ND Capital

Firms observed investing alongside OrbiMed, from public investor directories. Shared companies are the overlap with OrbiMed's recorded portfolio.

Similar investors

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Foresite Capital

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.

aMoon

aMoon is a healthcare and life sciences-focused investment firm that partners with scientists and entrepreneurs building companies at the convergence of technology and biology to transform healthcare and accelerate cures.

Basecamp Fund

A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.

$100K – $10M

Alumni Ventures

Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.

$100K – $10M

Featured in lists

Investors & VC Firms in North America Seed Investors & VC Firms Investors & VC Firms in United States Series A Investors & VC Firms Seed Investors & VC Firms in North America Investors & VC Firms in Europe Seed Investors & VC Firms in United States Investors & VC Firms in Global AI & Machine Learning Investors & VC Firms Growth Investors & VC Firms Series A Investors & VC Firms in North America Healthtech Investors & VC Firms

Website & social

orbimed.com

/orbimed-advisors @orbimed watch video

signal ↗crunchbase ↗

As published on the firm's website.

FoxScore

Combines investment activity, responsiveness, founder feedback, closing rate and follow-through reported by founders on Fox. Sign up to see it.

Your history

OrbiMed isn't in your CRM yet.

+ Add to CRM

Track outreach, deck opens, and next steps across your whole raise.

✨ Smart outreach

✨ Best warm path

Funds

ORBIMED ASIA PARTNERS III, L.P.Aug 2026 · 120 LPs$2.1BAUM

ORBIMED PRIVATE INVESTMENTS X, LPAug 2026 · 209 LPs$1.6BAUM

ORBIMED ASIA PARTNERS IV, L.P.Aug 2026 · 135 LPs$1.4BAUM

ORBIMED PRIVATE INVESTMENTS VII, LPAug 2026 · 145 LPs$1.1BAUM

OrbiMed Royalty & Credit Opportunities VAug 2026 · 237 LPsLPs: Kern County Employees' Retirement Association$1.1BAUM

ORBIMED ASIA PARTNERS V, LPAug 2026 · 95 LPs$947.9MAUM

ORBIMED ROYALTY & CREDIT OPPORTUNITIES V OFFSHORE, LPAug 2026 · 63 LPs$788.6MAUM

ORBIMED GENESIS MASTER FUND, L.P.Aug 2026 · 128 LPs$747MAUM

ORBIMED ASIA PARTNERS VI, LPAug 2026 · 77 LPs$684.8MAUM

ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV OFFSHORE, LPAug 2026 · 154 LPs$567.9MAUM

ORBIMED PARTNERS MASTER FUND LIMITEDAug 2026 · 126 LPs$535.1MAUM

ORBIMED ISRAEL PARTNERS II, L.P.Aug 2026 · 116 LPs$298.5MAUM

+7 more funds · also operates 1 SPV

Source: SEC Form ADV Schedule D and EDGAR Form D filings. AUM is gross asset value as reported by the adviser.

Latest on 𝕏

OrbiMed @orbimed

Congratulations to our portfolio company, Forte Biosciences, on its agreement to be acquired by @argenxglobal for $2.2 billion. This milestone follows impressive progress for Forte's lead program, FB102, including positive Phase 1b data in both vitiligo and celiac disease. With https://t.co/Tn0CXfP33r

Jul 27, 2026 · ♥ 6 · ⇄ 1

OrbiMed @orbimed

Congratulations to @Crinetics on its agreement to be acquired by Vertex Pharmaceuticals for $10B! OrbiMed has been proud to support Crinetics throughout its journey since 2018—from advancing a novel scientific platform to backing its IPO and beyond. This acquisition is a https://t.co/mRv6zuBn4p

Jul 7, 2026 · ♥ 2

OrbiMed @orbimed

We're proud to partner with The Oncology Institute on its strategic refinancing, providing a new $75 million term loan that strengthens the company's balance sheet, extends debt maturities, and enhances financial flexibility. We appreciate the opportunity to support The Oncology https://t.co/33MY8DliIQ

Jul 7, 2026 · ♥ 2